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Beta-thalassemia is one of the most common diseases related to the 
hemoglobin protein.  In this disease, the beta-globin gene is mutated, causing 
severe anemia and ineffective erythropoiesis.  Patients can additionally present 
with a number of life-threatening co-morbidities, such as anemia and iron 
overload.  Current treatment involves transfusion and iron chelation; allogeneic 
bone marrow transplant is the only curative option, but is limited by the 
availability of matching donors and graft-versus-host disease.   
As this diseases is a monogenic disease, it makes an attractive setting for 
genetic therapy at the RNA and DNA level.  At the DNA level, gene therapy aims 
to correct the mutated beta-globin or add back a functional copy of beta-globin.  
Initial gene therapy work was done with oncoretroviral vectors, but has since 
shifted to lentiviral vectors.  Currently, there are a few clinical trials and preclinical 
tests underway to test the curative potential of some of these lentiviral vectors, 
including our new gene therapy vector described here with the ankyrin insulator.   
IVS2-745 is a splicing mutation that occurs in intron 2 of the beta-globin gene.  It 
creates an aberrantly spliced form that incorporates an extra exon and leads to a 
premature stop codon.  Here we report novel uniform 2’-O-methoxyethyl (2’-
MOE) splice switching oligos (SSOs) to reverse this aberrant splicing.  Lead 2’-
MOE SSOs were generated to redirect splicing in the IVS2-745 pre-mRNA.  
With these lead SSOs we have demonstrated aberrant to wild type splice 
switching.  This switching led to an increase from 3-6% to up to 80% HbA in 
erythroid cells from thalassemic patients.  Furthermore, we have demonstrated a 
restoration of the balance between beta-like chains and alpha chains, and up to 
an 87% reduction in toxic alpha-heme aggregates.  While next examining the 
potential benefit of 2’MOE SSOs to patients with a sickle-thalassemic genotype, 
we observed reduced sickling as a result of 2’MOE SSO induced HbA.  In 
summary, 2’MOE-SSOs are a promising therapy for splicing forms of beta-
thalassemia.  Their ability to functionally modulate the thalassemia phenotype by 
correcting the underlying splicing cause offers a pharmacological treatment that 
is both direct and specific. 
 
 
 
iii 
 
BIOGRAPHICAL SKETCH 
 
Alisa Dong received her B.S. in Bioengineering from Berkeley in 2009. After 
graduating, she worked at Genentech in Process Development and Early Stage 
Research; then with John Hogenesch on circadian rhythms at the University of 
Pennsylvania. In 2012, Alisa joined the Rivella lab when it was still at Cornell Weill 
for her PhD dissertation. She currently works as an in abstentia graduate student 
with Stefano Rivella at the University of Pennsylvania and The Children's Hospital 
of Philadelphia on gene therapy and splice switching treatments for thalassemia 
and sickle cell anemia.   
  
iv 
 
This work is dedicated to my family, colleagues, and friends who have supported 
and pushed me throughout my life.   Most of all, to my loving mom, Adrienne 
Dong, who I know is smiling down on me with pride for going to, and completing, 
graduate school, to my cooler than ever dad, Calvin Dong, who always knows I 
have fun and work hard, and to my sister Courtney Dong, who I still remember 
waking me up (loudly) for school every day, and who has set an example to 
emulate throughout my life.   
 
This PhD would not have been possible if not for my amazing labmates and 
mentors.  Stefano gave me the pushes I needed to proceed with projects, and 
make it to the end of this journey.  As for Laura, as soon as I met you, I wanted to 
be like you:  a strong, independent, intelligent, and deeply caring person.  Every 
time I had a personal or professional setback, you were there to pick me up, 
understand, and push me forward.  My labmates have been there to help me 
pipet, feed my cells, cry with me over good times and bad, laugh with me, and 
best of all – dance with me.  Truly, my best friends are in the lab.  Ritama, you 
have been there all along.  We’ve carried each other through hurdles since our 
first Indian dinner in Lasdon to Dorian’s.  Silvia, the move to Philadelphia would 
have never been the same without your caring, your understanding, and your 
dancing.  Roberta, there will be no one as considerate and thoughtful as you.  
Valentina “Valleeee” stay feisty my beach.  Dane, life would just not be as funny 
and melodical without you and your enabling.  Ricardo, it took a little time to 
break you, but the friendship, the support cuddles, even the judging and eye 
rolling was all worth it. To all my interns, thank you for your dedication and 
countless hours of bacteria work.  And finally, in loving memorium, to the 
unforgettable, sticking-her-tongue-out, kicks-of-love, best-time-in-New York 
Chiara Gemmo, I’ll see you on the other side.   
  
v 
 
ACKNOWLEDGEMENTS 
This work has been supported by the:  ThalaMoSS Grant, NHLBI R01 (NHLBI-
5R01HL102449 to S. Rivella) and the European Community grant (FP7-
HEALTH-2012-INNOVATION to L.B. and S.R.), Associazione Veneta per la Lotta 
alla Talassemia (AVLT, IT to L.B.).  The authors gratefully acknowledge the 
generous support by the Jean and DiGaetano families and the Children’s 
Hospital of Philadelphia Foundation.   
 
 
 
  
vi 
 
TABLE OF CONTENTS 
Biographical Sketch iii 
Dedication iv 
Acknowledgements v 
Table of Contents vi 
List of Figures vii 
List of Tables viii 
List of Abbreviations ix 
Chapter One:  An Introduction to genetic approaches for the treatment 
of beta-thalassemia 
1 
Chapter Two:  Results:  Adult Hemoglobin Production, Chain 
Rebalance, and Splice Correction in IVS2-745 Beta-thalassemia Patient 
Cells Using 2’-O-methoxyethyl Splice-Switching Oligos  
30 
Chapter Three:  Methods 40 
Chapter Four:  Discussion and Future Perspectives 47 
References 50 
Appendix:  Patent Application for ALS10, a new gene therapy vector 60 
  
  
  
 
  
vii 
 
LIST OF FIGURES 
Chapter One 
1. Schematic of gene therapy for beta-thalassmia and sickle cell 
anemia. 
4 
2.  Mixed chimerism 19 
 
Chapter Two 
1. Treatment of heterozygotic patient samples with a 745/β0 genotype 
with splice-switching oligos 
31 
2.  Full gels, including all triplicates, of Figure 1A.    33 
3.  Representative HPLC profile of the separation of hemoglobins 34 
4. Treatment of homozygotic samples with a 745/745 genotype with 
splice-switching oligos 
35 
5. Chain rebalance and inhibition of in vitro sickling with splice switching 
oligos 
37 
6.  Viability and Differentiation 39 
 
Chapter Three-Four 
None 
Appendix 
1. A comparison of levels of HbF with integration of GG1-SA 68 
2. Levels of HbF and HbS in pCL-ZF-Ldb1 treated SCD erythroblasts 69 
3. Quantification of tetrameric and single chain globins in untreated 
and pCL-ZF-Ldb1 treated SCD erythroblasts 
70 
 
4.  Quantification of HbS in untreated and pCL-ZF-Ldb1 treated SCD 
erythroblasts 
71 
5. Gamma-globin repressor expression 72 
6.  HbF increase and HbS decrease in pCL-ZF-Ldb1 treated and HbF 
inducer treated SCD erythroblasts 
73 
7. Single chain globins analysis in pCL-ZF-Ldb1 treated erythroblasts 74 
8.  Trend of HbF levels in SCD erythroblasts at steady state 75 
9.  Cytotoxicity and dose/response calibration 76 
10.  Variation of HbF % in SCD erythroblasts treated at various times 77 
11.  Graphical maps of vectors 78 
12.  Graphical summary of HbA in erythroblasts from patients with 
β0/+ or β0/0 thalassemia treated with AnkT9W or ALS10 
79 
13. ZF-Ldb1 sequence 80-87 
14.  ALS10 sequence 88-107 
15. non-mutated beta-globin cDNA sequence 108 
 
viii 
 
LIST OF TABLES 
Chapter One 
1. Beta-globin gene therapy vectors 8 
2. Gamma-globin gene therapy vectors 11 
 
Chapter Two-Four 
None 
 
Appendix 
1. Experimental Flow for the expansion and treatment of CD34+ cells 
from patients with sickle cell anemia with pCL-ZF-LDB1 
119 
2. Experimental Flow for the expansion and treatment of CD34+ cells 
from patients with sickle cell anemia with pCL-ZF-LDB1 or HbF inducers 
119 
  
ix 
 
LIST OF ABBREVIATIONS 
2'MOE 2’-O-methoxyethyl  
AAVS1 adeno-associated virus preferred integration site 1 
Ank ankyrin element 
BERK Berkeley mouse model 
BM bone marrow 
BMT  bone marrow transplant 
bpA bovine growth hormone polyadenylation symbol 
EMH extra medullary hematopoiesis 
G-CSF granulocyte colony-stimulating factor  
GFP green flourescent protein 
GPA glycophorin A 
Hb hemoglobin 
HbA adult hemoglobin 
HbF fetal hemoglobin 
HbS sickle hemoglobin 
HMGA2 high mobility group AT-hook 2 
HPFH hereditary persistance of fetal hemoglobin 
HPLC High performance liquid chromatography  
HSC hematopoietic stem cell 
HSVtk  herepes simplex virus type 1 thymidine kinase  
iCASP9 inducible caspase 9 
IE ineffective erythropoiesis 
iPSC induced pluripotent stem cells 
IRES internal ribosomal entry site  
IVS intravenous sequence 
LCR locus control region 
LTR long-terminal repeat 
MDR1 multidrug resistance 1  
MEL mouse erythroleukemia cells 
NTDT non-transfusion dependent thalassemia 
PB peripheral blood 
PBMC peripheral blood mononuclear cells 
RRE rev response element 
SAD S-Antilles-D Punjab mouse model  
SCA sickle cell anemia 
SCD sickle cell disease 
SSO splice switching oligos 
TALENs transcription activator-like effector nucleases  
TCP Tranyl-cypromine 
x 
 
TR1 transferrin receptor 1 
UTR untranslated region 
VCN vector copy number 
WHO World Health Organization 
WPRE Woodchuck Post-Regulatory Element  
ZF zinc finger 
 
 
1 
 
Chapter One 
An Introduction to genetic approaches for the treatment of beta-
thalassemia 
 
Sickle cell anemia (SCA) and beta-thalassemia are the most frequently 
inherited blood disorders worldwide.  Altogether, roughly 100,000 Americans are 
affected by these disorders.  Both disorders are characterized by mutations in the 
beta-globin gene, a subunit of hemoglobin (Hb).  SCA is an inherited disorder 
characterized by only a single mutation in the beta-globin gene, leading to the 
formation of hemoglobin S (HbS) (1). HbS exhibits a marked decrease in 
solubility, and an increase in viscosity and polymer formation.  Ischemic stroke, 
caused by large vessel arterial obstruction with superimposed thrombosis is one 
of SCA’s most devastating complications. Blood transfusions are administered to 
prevent thrombosis. Unfortunately, periodic blood transfusions are associated 
with significant risks of iron overload and other complications, and must be 
accompanied by iron chelation (2, 3).  Beta-thalassemia on the other hand is 
characterized by one or more of over 300 various mutations in the beta-globin 
gene. Based on the combinations of these mutations, patients might be affected 
by a milder form, indicated as beta-thalassemia intermedia or non-transfusion 
dependent thalassemia (NTDT), or the most severe form, beta-thalassemia 
major (4, 5). Beta-thalassemia major requires regular transfusions to sustain life.  
However, due to the negative progression of this disease, very often NTDT 
patients become transfusion dependent as well (6, 7). Major problems are 
2 
 
progressive splenomegaly from extra medullary hematopoiesis and iron build-up 
in the heart and other organs, often resulting in fatal outcomes for some patients 
in their teens or early 20s (8, 9).  Current palliative therapeutic options to treat 
these two disorders are red blood cell transfusion and iron chelation (2, 10).  
In addition to life-threatening anemia, patients may present with inherent 
and treatment-related complications that exacerbate the pathology.  For patients 
with SCA, common complications include painful episodes, acute chest 
syndrome, and stroke (1); in patients with thalassemia, hepato-splenomegaly, 
recurrent infections, and spontaneous fractures (11-13).  In both cases, 
transfusion-associated infections and organ damage are side effects of long-term 
treatment and unsatisfactory iron chelation.  Iron overload is observed also in 
NTDT patients because of ineffective erythropoiesis (6, 14).  Ineffective 
erythropoiesis triggers a cascade of compensatory mechanisms resulting in 
erythroid marrow expansion, extramedullary hematopoiesis, splenomegaly, and 
increased gastrointestinal iron absorption (15).  Ineffective erythropoiesis triggers 
increased iron absorption by reducing the expression of hepcidin, the hormone 
that controls dietary iron absorption (14, 16-18). 
Although both transfusion and iron chelation treatments have remarkably 
improved over the years and, thus, improving the quality of life, they do not 
provide a definitive cure, as they do not address the inherent genetic cause.  To 
this end, hematopoietic stem cell (HSC) transplantation is the only presently 
available cure.  Allogeneic bone marrow transplant (BMT) can be curative, but 
only a small proportion of patients have suitable donors.  Furthermore, 
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myeloablative HSC transplantation carries a 5%–10% mortality rate.  Graft-vs-
host disease and adverse immune reactions can limit the success of allogenic 
BMT as well (9).  Given these limitations, gene therapy using a patients’ own 
HSCs represents an alternative and potential cure because it aims at the direct 
recovery of the hemoglobin protein function via the addition of a functional copy 
of the beta- or gamma-globin gene.  The development of gene therapy tools for 
SCA and beta-thalassemia has been the object of research of the last few 
decades and has been proved successful in mouse model studies, in vitro 
human cell studies, and thus far in one clinical trial.   
At the DNA Level:  Gene Therapy 
The conditions for a clinical-grade gene therapy vector can be summarized as 
follows.  Figure 1 provides a schematic of gene therapy and key issues found in 
each stage.     
(1) controlled transgene expression:  erythroid-specific, stage-
restricted, elevated, position-independent, and sustained over time 
(2) effective targeting of HSCs 
(3) highly efficient and stable transduction 
(4) absent or low genomic toxicity 
(5) correction of the phenotype in preclinical models.   
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Figure 1:  Schematic of gene therapy for beta-thalassmia and sickle cell anemia. 
Oncoretroviral Vectors 
 
 The first studies of gene addition were done with oncoretroviral vectors 
and helped paved the way for current lentiviral vectors.  Oncoretroviruses, like 
lentiviruses, belong to the Retroviridae family and are RNA-based viruses(19).  
Multiple studies showed oncoretroviruses are capable of transferring genetic 
material without transferring any viral material, and are able to achieve 
expression of human beta-globin in murine cells.  However, the expression of 
beta-globin was extremely low and nowhere near therapeutic (20-22). 
 Studies then moved on to determining what other elements needed to be 
incorporated to achieve higher beta-globin expression.  Discovery of the locus 
control region, or LCR, brought significant advancements to vector design.  The 
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LCR is a regulatory region upstream of the beta-globin locus and is critical for 
high-level, sustained, erythroid-specific, and position-independent globin 
expression (23, 24).  The LCR is made up of four DNaseI hypersensitive sites 
(HS) that contain many motifs for transcription factors and chromatin remodeling 
factors.  It is thought to regulate globin gene expression through a looping 
mechanism, bringing various transcriptional modifiers to the globin promoter (25).  
Incorporation and modification of these HS sites was done in a number of works.  
Work by Plavec et al in 1993 (26) showed HS2, HS3, and HS4 elements 
increased beta-globin expression by 10-fold in mouse erythroleukemia (MEL) 
cells, but still remained relatively low for mice transplanted with oncoretrovirus-
transduced cells:  0.04%-3.2% of endogenous mouse beta-globin RNA.  
Furthermore, there were problems with stability and high viral titer production.  
Leboulch and coworkers (27) undertook modification of the LCR in order to 
overcome these problems.  They saw instability in all combinations of LCR 
sequences, with HS2 alone conferring a single common rearrangement and 
other combinations showing multiple rearrangements.  Beta-globin gene 
mutagenesis and elimination of a 372 base pair intronic sequence and multiple 
reverse polyadenytlation and splice sites resulted in higher titer viruses and more 
stable proviral transmission.  Sadelain saw additional success in 1995 (28) with 
producing a high-titer retroviral beta-globin vector, but unfortunately the vector 
did not give high position-independent expression and large clonal variation was 
seen. 
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 Other methods were also tested for their ability to achieve therapeutic 
levels of expression:  addition of a chromatin insulator (29); use of the ankyrin 
promoter driving the gamma-globin gene (30); use of a mutant gamma-globin 
enhancer characterized from patients with hereditary persistence of fetal 
hemoglobin (HPFH) driving gamma globin (31);  addition of the HS40 regulatory 
region from the human alpha-globin gene locus  (32); and use of an anti-sickling 
beta-globin (33).  Many important insights were gained by these experiments, 
however, as with other oncoretroviral studies, their success was limited.  
Eventually oncoretoviral studies gave way to the lentiviral studies discussed 
below. 
Lentiviral Vectors 
In the mid-1990s, lentiviral vectors based on the human immunodeficiency 
virus (HIV-1) arose as an option for gene transfer.  Engineered to be devoid of 
any pathogenic or replication competency, these viruses are efficiently able to 
encompass large therapeutic transgene cassettes.  Like all retroviruses, 
lentiviruses exhibit receptor-mediated entry, capsid uncoating, reverse 
transcription, and integration into the host genome (19).  However, lentiviruses 
have a more intricate genome, notably the Rev response element, or RRE.  The 
RRE helps stabilize the proviral RNA by interacting with the viral protein Rev. 
This allows for stronger unspliced RNA export from the nucleus (19, 34, 35).  
Another important element discovered in lentiviruses is the central polypurine 
tract/central termination sequence element.  The cPPT/CTS element is a short 
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noncoding part of the pol gene sequence that increases lentiviral transduction 
efficiency. 
Importantly, for hematological gene therapy purposes, lentiviruses are 
able to infect dividing and non-diving cells (36).  Gene therapy for hematological 
disorders typically infect HSCs, so that the genetic modification is passed on 
short term to differentiating cells, and long-term to more stem cells through self-
renewal.  HSCs, however, are difficult to culture and transduce ex vivo due to a 
delicate balance between dividing/proliferation and engraftment potential.  
Normally, proliferation and engraftment potential are negatively correlated: 
increasing the proliferation is detrimental because the cells subsequently do not 
engraft (37).  Thus, ability to infect non-dividing cells that retain engraftment 
potential is an extremely beneficial property of lentiviruses.  Lentiviruses 
containing regulatory elements, promoters, enhancers, and beta-globin or 
gamma-globin have been successful with correction of mouse models of 
thalassemia and SCA, and with in vitro correction of human CD34+ peripheral 
blood (PB) cells.  A list of beta-globin vectors can be found in Table 1.   
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Table 1:  Beta-globin vectors 
 
In 2000, May (38) and colleagues used the TNS9 vector to correct a 
mouse model of thalassemia intermedia.  Later in 2003, Rivella (39) and 
colleagues showed that this same vector could be used to rescue lethality in a 
new model of Cooley’s anemia (thalassemia major).   TNS9 exhibits position-
effect variation though, and in the Cooley’s anemia model, was unable to be 
therapeutic in all mice, with average human beta-globin expression between 3.6 
and 9.4 g/dL.  Two mice models of SCA were corrected in 2001 by Pawliuk (40) 
and colleagues:  the S-Antilles-D Punjab model (SAD) and the Berkeley (BERK) 
model.  The SAD mouse model expresses human alpha and a human “super S” 
beta-globin that has two point mutations(41).  The BERK model expresses 
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human alpha and human sickle beta-globin, but additionally does not express 
any endogenous mouse alpha or mouse beta globin (42).  As a result, the BERK 
model has a more severe phenotype, in part because of suboptimal expression 
of the human beta-globin gene as compared to the endogenous mouse gene.  
Pawliuk used a transgenic “βT87Q” form of beta-globin, an antisickling mutant 
form which has an amino acid substitution at the 87th position.  With this vector, 
Pawliuk saw transgenic Hb could make up to 12% and 52% total Hb for the SAD 
and BERK models, respectively.  In 2013, another antisickling mutant form was 
tested with three point mutations:  T87Q for blocking the lateral contact with HbS, 
E22A to disrupt axial contacts with HbS, and G16D, which confers a competitive 
advantage over HbS for interaction with alpha-globin (43).  Named “CCL-βAS3-
FB”, this vector could reduce the relative amount of sickled red blood cells 
differentiated in vitro; and, using vector copy numbers of 0.5-2, could make up 
15-25% of total Hb. 
In order to increase the safety of lentiviral vectors and improve expression, 
insulators were tested by Puthenveetil in 2004 (44).  An insulator is a genetic 
element which usually has two properties:  (1) enhancer-blocking activity, when 
placed between an enhancing element and a promoter and (2) preventing the 
spread of heterochromatin into the integrated transgenic cassette from a nearby 
heterochromanized region (45-47).  By adding an insulator, one can prevent the 
beta-globin LCR from acting on nearby oncogenes it might have integrated near.  
It can also help reduce vector silencing, to ensure sustained and high transgene 
expression.  Puthenveetil et alt’s vector, named BG-1, added a 1.2 kb cHS4 
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insulator, taken from the chicken beta-globin hypersensitive site 4.  As reviewed 
by Nienhuis and Persons (48), the cHS4 insulator has a “core” that contains five 
footprints.  The footprints are involved in:  recruiting CTCF, an enhancer blocking 
protein; binding USF proteins in order to recruit histone-modification enzymes 
that make transcription-activation marks; and binding VEZF1, which prevents 
DNA methylation in the transcribed region.  Human beta-thalassemic cells 
treated with BG-1 and differentiated in vitro showed similar amounts of 
hemoglobin as non-thalassemic controls.  Upon transplantation into 
immunodeficient mice, treated cells underwent effective erythropoiesis and 
expressed normal amounts of beta-globin.  In 2007, Arumugam (49) and 
colleagues compared vectors with the cHS4 insulator to those without and 
consistently saw approximately double the beta-globin expression with the 
insulator in vitro with MEL cells and in vivo with transplanted and transduced 
murine HSCs.  While beneficial to expression, the 1.2kb cHS4 insulator causes 
low viral titers.  Thus, in 2009, Arumugam (50) identified a 400 bp extended core 
region of the cHS4, that still exhibits full insulator activity but does not have a 
severe an impact on titer.  They found the previously identified core only reduced 
clonal variegation.  
Further studies have also been done on the LCR.  In 2007, Lisowski et alt 
(51) showed addition of HS1 from the LCR to HS2-4 significantly increased 
globin expression.  Miccio in 2008 (52) used a “GLOBE” vector containing the 
HS2 and HS3 regions without the HS4 region.  They used it to rescue Cooley’s 
anemia lethality, but high copy numbers were required for correction (34).  
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Interestingly, upon transplantation, transduced cells expressing a high level of 
beta-globin were preferentially selected in vivo.  Roselli (53) produced preclinical 
data using the “GLOBE” vector in 2010 on a diverse set of CD34+ patient 
samples to restore adult Hb (HbA) synthesis.  Integration analysis revealed 
integration preference in transcriptionally active regions but no preference for 
cancer-related regions.  “GLOBE” was later modified into “G-GLOBE” by adding 
the HS2 enhancer of the GATA-1 gene (54); it too could achieve high expression 
of beta-globin.  The GATA-1 HS2 bound GATA1 and CBP acetyltransferase, 
leading to the establishment of an open chromatin region. 
Table 2:  Gamma-globin vectors 
 
Lentiviral transduction of gamma-globin has additionally been shown to be 
therapeutic.  Table 2 lists gamma-globin vectors that have been successfully 
used.  In 2003, Persons (32) et al developed the “d432βAγ” vector, which 
expressed gamma-globin under beta-globin LCR elements.  Although they saw 
expression of fetal hemoglobin, they still saw high variation due to position and 
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vector copy number.  Hanawa in 2004 (55) used a longer LCR to achieve more 
consistent expression across animals.  In 2006, Samakoglu (56) and colleagues 
showed that a combination vector could be made that expressed gamma-globin 
and concurrently knocked-down sickle beta-globin via small hairpin RNA.  They 
tested this vector on HeLa and MEL cells stably expressing sickle beta globin.  
The discovered that the placement of the shRNA was critical, as it affected 
interferon response, siRNA production, and the amount of gamma-globin 
expression.  Pestina (57) tested a gamma-globin vector in vivo on the BERK 
SCA model.  The gamma-globin was modified to contain a 3’UTR from beta-
globin, since proteins are believed to bind the beta-globin 3’UTR and increase 
mRNA stability.  This was further modified by Wilber in 2011 (58) with the 
addition of the 400bp core of the cHS4 insulator, and tested on human CD34+ 
PB cells from three beta-thalassemia patients.  They saw fetal Hb (HbF) 
production ranged between 45-60% of total Hb, and up to a 3 fold increase in 
total Hb content.  Papanikolaou in 2012 (59) published a report of a gamma-
globin virus without the LCR, but instead containing a gamma-globin promoter 
with a -117 point mutation associated with HPFH, the HS40 enhancer from the 
alpha-globin locus, the HPFH-2 enhancer, and the cHS4 insulator.  They saw 
mild improvement of HbF synthesis compared to mock-transduced controls.  
Most recently, our laboratory has done work to find new insulators.  The 
aforementioned cHS4 insulator is subject to rearrangements and loss (see 
Clinical Trials, below).  To this end, we generated a new lentiviral vector, which 
we have named AnkT9W. AnkT9W contains the erythroid-specific ankyrin 5′ 
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hyper-sensitive barrier insulator (60, 61).  This insulator does not exhibit 
enhancer-blocking activity, but does prevent the spread of heterochromatin, and 
significantly increases expression of beta-globin as compared to vectors without 
this insulator.  This vector was able to maintain high, yet stable levels of Hb 
synthesis in MEL cells and human CD34+ PBMCs.  Analysis indicated that in 
MEL cells, AnkT9W expressed the transgenic mRNA and hemoglobin at higher 
levels than the parental T9W (a modified TNS9).  Interestingly, AnkT9W was 
additionally able to correct the phenotype of SCA cells by modifying the 
proportion of sickling vs functional Hb, without changing the overall Hb content. 
This could be clinically relevant since there is a concern that adding transgenic 
beta-globin into SCD HSCs increases the total amount of beta-chains, both sick 
and transgenic.  This new total amount might exceed the amount of α-chains, 
leading to an alpha-thalassemia like phenotype. 
Addition of Non-globin Genetic Elements  
 On top of the numerous studies to add back beta and gamma globin 
genetic sequences, there are have been additional studies based on adding 
other genetic elements which can modify beta or gamma-globin gene expression.  
The gamma-globin repressor BCL11A has been identified as target to increase 
gamma-globin gene expression.  Xu and colleagues were able to demonstrate 
that affecting BCL11A alone was able to increase endogenous gamma-globin 
expression and ameliorate the sickle cell phenotype in mice(62).  Since Bcl11A 
knockout is postnatal lethal, they used a floxed Bcl11A mice crossed with the 
EpoR-GFP Cre mice, which express Cre recombinase under the erythropoietin 
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receptor promoter.  As in the full Bcl11A knockout, the switch from HbF to HbA 
did not occur.  These mice were then bred with SCD mice.  In the combination 
SCD/Bcl11Afl/fl mice, sickle cells were absent and blood parameters were 
markedly improved, thus showing that Bcl11A deletion alone was sufficient to 
ameliorate SCD.  Along the same lines, Wilber and colleagues (58) tested a 
lentiviral construct encoding a BCL11A shRNA on CD34+ human PB cells and 
saw a 3-fold increase in gamma-globin expression.  Most recently, Bauer and 
colleagues (63) have done a genome-wide association study concerning Bcl11A.  
They found a sequence in intron-2 that causes developmentally restricted, 
erythroid-specific lacZ reporter expression in mice.  Disruption of this sequence 
with transcription activator-like effector nucleases (TALENs) in MEL cells lead to 
reduced expression of Bcl11A.  As such, this sequence might be a new target to 
lower Bcl11A expression and increase HbF production. 
 Oct-1 is another gene that negatively regulates gamma-globin gene 
expression.  Oct-1 is a transcription factor that recognizes the octamer 
ATGCAAAT.  The gamma-globin promoter contains three Oct-1 consensus 
sequences.  The -175 consensus sequence has been shown to be associated 
with HPFH and mutagenesis of the -280 consensus sequence leads to increased 
gamma-globin expression.  Xu and colleagues (64) tested the ability of a “decoy 
oligonucleotide” to compete for Oct-1 binding, therefore reducing Oct-1 binding at 
the endogenous gamma-globin locus.  In K562 cells, they saw an increase in 
gamma-globin gene expression after addition of the decoy oligonucleotide. 
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 Genetic elements can also be engineered to affect beta and gamma-
globin gene expression.  Advances in zinc-finger (ZF) development have allowed 
the creation of domains able to recognize any 18 base pair DNA sequence.  ZF 
domains can be paired with transcriptional activation domains to create “artificial 
transcription factors”.  In 2010, Wilber and colleagues (65) extensively examined 
one such engineered ZF transcription factor, termed GG1-VP64.  GG1-VP64 
recognizes the -117 position of the gamma-globin promoter.  The -117 position is 
the site of a naturally occurring mutation which causes HPFH, and is thus a 
known region important for modulating gamma-globin gene expression (66).  
They discovered in wild-type CD34 PB cells that up to 20% HbF could be 
produced, as compared to 2% in untransduced controls.  Later in 2011(58), they 
tested beta-thalassemic samples and found a therapeutic 20-fold increase in 
gamma-globin could be achieved.  In 2012, Deng et alt published a paper 
concerning an artificial ZF linked to the protein Ldb1 (25).  Ldb1 is a critical part 
of GATA1-mediated chromatin looping of the LCR to the beta-globin promoter.  
Deng and colleagues created Ldb1-ZFs that recognized the beta-major promoter 
(P-ZF) or the HS2 site of the LCR (L-ZF).   They showed in murine GATA-1 null 
cells that beta-major expression could be induced by P-ZF alone or P-ZF and L-
ZF, but not by L-ZF alone.  Furthermore, they showed that the self-association 
domain of Ldb1 was sufficient for this activity as well (25).    
Clinical Trials 
The first successful gene therapy trial for beta-thalassemia was done in 
Paris and reported by Leboulch in 2010 (67).  It was a small trial involving only 
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two patients.  The first patient failed to engraft due to technical issues unrelated 
to the vector.  The second patient, however, has been transfusion independent 
now for several years.  The patient is a compound heterozygote (βE/β0), in which 
one allele (β0) is nonfunctioning and the other (βE) is an HbE mutant allele 
whose mRNA may either be spliced correctly (producing a mutated βE-globin) or 
incorrectly (producing no beta-globin). 
The βT87Q LentiGlobin vector was used for this trial (see Table 1).  As 
with the βT87Q vector, this vector expresses a mutated beta-globin 
distinguishable from transfused beta-globin due to an anti-sickling mutation at the 
87th amino acid.  It also contains two core copies of the cHS4 insulator.  Analysis 
of the patient’s transduced cells revealed an intact coding sequence for the 
vector, however, with the loss of one copy of the cHS4.  Of the twenty-four 
chromosomal integration sites (IS) found, one of the sites, high mobility group 
AT-hook 2 (HMGA2), caused transcriptional activation of HMGA2 and became 
the dominant clone.  Cells from the clinical trial patient with a HGMA2 IS showed 
loss of the 3'UTR of HGMA2, preventing the binding of let-7 miRNAs to 
complementary sequences.  Erythroid cells from the HMGA2 clone exhibited a 
dominant, myeloid-biased cell clone.  HMGA2 mRNA was undetectable in 
granulocyte-monocytes, thus the expression was reported to be erythroblast-
specific.  However, the clonal dominance of HMGA2 was represented in all 
populations in similar proportions (erythroblasts, granulocyte-monocyte and LTC-
IC cells).  The authors hypothesize that this dominance is due to a transient 
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expression of HMGA2 in a myeloid-restricted LT-HSC during β-LCR priming, 
before the β-LCR becomes restricted to the erythroid lineage.  
Overexpression of HMGA2  is found in a number of benign and malignant 
tumors and can lead to a clonal growth advantage (68).  Overexpression is often 
associated with mutations affecting the 3' untranslated region (UTR), which 
contains binding sites for the regulatory miRNA let-7 (68).  Let-7 miRNA binding 
to the 3’UTR of HMGA2 negatively regulates HMGA2 mRNA and thus the level 
of protein expression (69).Transgenic mice carrying a HMGA2 with a shortened 
3’UTR expressed increased levels of HMGA2 protein in multiple tissues including 
hematopoietic cells.  These mice showed splenomegaly, erythropoietin-
independent erythroid colony formation, and an increased number of peripheral 
blood cells in all lineages.  Furthermore, BM cells derived from these animals had 
a growth advantage over wild-type cells. Thus, overexpression of HMGA2 is 
associated with clonal expansion at the stem cell and progenitor levels (68). 
At the time of reporting, the patient had been transfusion-independent for 
two years, and showed stable Hb levels from 9-10 g/dL-1.  The patient has 
undergone frequent phlebotomies to increase iron clearance.  Therapeutic Hb-
βT87Q LentiGlobin however only accounted for 1/3 of the total Hb, with 
endogenous HbE and HbF making up the rest. Without the additive effect of 
these endogenous Hb’s, this first trial might not have been a success. This 
suggests that we not only need a predictive in vitro model with which to evaluate 
potential trial patients, but better vectors that can achieve higher therapeutic Hb 
expression. 
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Currently the first United States phase I clinical trial has received FDA 
approval and is enrolling patients.  The strategy was briefly described by 
Sadelain and colleagues in 2010 with the main goals of assessing insertional 
oncogenesis & replication-competent lentivirus safety, and determining levels of 
engraftment & vector expression (70).  The study plans to use CD34+ cells 
mobilized by granulocyte colony-stimulating factor (G-CSF).  Using G-CSF, 
Sadelain et al have already achieved successful mobilization of CD34+ cells in 
three beta-thalassemia patients in amounts sufficient for transduction.  In 2002 Li 
et al (71) studied G-CSF peripheral blood stem cell mobilization in beta-
thalassemia patients and found up to a 21.5 fold increase in CD34+ cells could be 
collected.  In 2012, Yannaki and colleagues studied different mobilization 
methods in 23 patients with beta-thalassemia (72).  They studied patients with or 
without splenectomy, and found that non-splenectomized patients tolerated G-
CSF, but splenectomized patients could not tolerate it without a one-month 
pretreatment with hydroxyurea.  They additionally examined Plerixafor, which 
reversibly inhibits the CXCR4-SDF1 interaction with the BM microenvironment, to 
mobilize HSCs.  Plerixafor proved successful for both splenectomized and non-
splenectomized patients. 
For the Sadelain trial, the previously described TNS9 vector (38, 39) will 
be used to induce transgenic expression of beta-globin. Small unpublished 
modifications have been made to this vector to increase titer, but the gene, 
promoter, enhancers, and LCR remain intact. Two more trials are also in the 
works.  (1) A trial St. Jude Children’s Research Hospital is planned using 
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gamma-globin coding sequences under control of the beta-globin promoter.  (2) 
The company Bluebird Bio, a company specializing in genetic and orphan 
diseases, is planning a trial in the San Francisco area using a LentiGlobin BB305 
T87Q virus.  The identifiers for the TNS9, gamma-globin, and LentiGlobin trials 
are NCT01639690, NCT00669305, and NCT01745120, respectively; and at the 
time of writing were all recruiting participants. 
Figure 2:  Mixed Chimerism.  White: starting bone marrow of the patient before 
procedure; Textured Grey: Bone marrow that has been cultured but not 
transduced; Black: Bone marrow that has been cultured and successfully 
transduced with therapeutic vector.  Ex-vivo expansion would increase the total 
amount of bone marrow that been cultured.  More toxic myeloablation would 
decrease the amount of residual bone marrow.  Selection with MGMT or MDR1 
would increase the amount of vector transduced cells. 
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Mixed Chimerism and In Vivo Selection of Transduced Cells 
When undergoing autologous stem cell transplant, patients first need to 
undergo a myeloablative conditioning regimen.  The success of conditioning 
regimen intensity depends on a balance between toxicity and the amount of 
mixed transgenic-chimerism, i.e. the amount of BM made up of transplanted cells 
that carry the vector (Figure 2).  Full myeloablation can, theoretically, result in a 
complete transgenic-chimerism, where the BM is made entirely of cultured cells, 
with a greater amount of therapeutic vector-transduced cells than in a partial 
myeloablation setting.  However, full myeloablation is more toxic and puts the 
patient at greater risk, especially in the case of graft failure.  A reduced-intensity 
conditioning regimen can be less toxic, however it can also lead to a lower 
composition of therapeutic vector-transduced cells due to lower transgenic-
chimerism.  When a reduced-intensity conditioning regimen is used, beta- globin 
expression from the vector must be high enough to give transduced cells a 
survival advantage compared to untransduced cells.  In studies done of 
traditional allogeneic BMT, patients with as low as 20% donor contribution were 
still able to achieve transfusion independence and normal hemoglobin levels.  
However, a high initial engraftment (>90% at sixty days post-transplant) is 
necessary for good chances of stable mixed chimerism (9).   
Lucarelli and colleagues identified three Pesaro risk classes for beta-
thalassemia patients based on previous iron chelation, hepato- and 
splenomegaly, and liver fibrosis (73).  Patients with irregular iron chelation and 
more liver damange fall into class 3 while those patients with less iron overload 
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and liver damage fall into class 1 and 2.  A study of 886 beta-thalassemia 
patients who received transplants from HLA-matched siblings or parents showed 
a 91% and 84% probability of Thalassemia-free survival with a normal 
conditioning regimen for class 1 and class 2 patients, respectively(74).  There 
has been a recent trend to lower-intensity, non-myeloablative conditioning 
regimens though based on the following data:  (1) lower morbidity and mortality is 
associated with these regimens, (2) patients not eligible for the traditional full 
myeloablative regimen have been safely transplanted with these regimens, and 
(3) mixed chimerism can be sustained and still lead to amelioration of disease in 
patients with allografts (75).  Multiple groups have had success with reduced-
intensity regimens with lower doses of busulfan, or by using alternatives such as 
thiotepa, treosulfan, fludarabine, busulfex, or antithmocyte globulin (as reviewed 
in (75, 76)).  All of these myeloablation reports, however, relate to beta-
thalassemia transplants with HLA-matched donors and not to autologous 
transplants done with vector-transduced cells.  The TNS9 trial with vector-
transduced cells will use a reduced-intensity regimen based off of data from 
successful allogeneic transplants (70) and data from autologous transplants with 
vector-transduced cells in immunodeficiency disorders(77, 78).  
 If after transplant a patient were to have a non-therapeutic level mixed 
chimerism, or suboptimal transgene expression, it would be helpful to have an in 
vivo strategy to increase the chimerism.  Conferring a cytoprotective drug 
resistance to lentiviral-transduced cells is one of these strategies.  The human 
multidrug resistance 1 (MDR1) gene, encodes a P-glycoprotein drug efflux pump 
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that confers resistance to several chemotherapy drugs, including paclitaxel and 
doxorubicin, both of which under normal conditions are hematopoietically toxic.  
Researchers discovered a modest positive selection of peripheral blood 
progenitor cells that had been transduced with MDR1 could be achieved by 
giving paclitaxel (79, 80).  In a second set of studies, researchers used a mutated 
MGMT gene.  MGMT encodes the enzyme O6-methylguanine-DNA 
methyltransferase, and confers resistance to nitrosoureas and O6-benzylguanine 
drugs.  A dual vector was created encoding both MGMT under a constitutive 
promoter and gamma globin under erythroid control elements (V5 from Table 1).  
Murine wild-type (81) and murine beta-thalassemic bone marrow (82) were 
transduced with this vector.   This dual vector was able to increase the number of 
fetal hemoglobin expressing cells in vivo after treatment with drug.  Furthermore, 
for thalassemic bone marrow, researchers could achieve amelioration of the 
anemia.  Researchers also showed that ex vivo selection of lentiviral-transduced 
and transplantable cells was possible.  They pretreated the cells with drug prior 
to transplantation and saw that a greater number a mice achieved therapeutic 
fetal hemoglobin levels as compared to untreated controls (82).   
 MGMT has been studied in both dogs (83) and non-human primates.  One 
study with non-human primates showed mostly mild and transient enrichment of 
MGMT-transduced cells (84), while another group showed more stable 
enrichment (85).  The dog (83) and one non-human primate study (85) showed 
no significant enrichment for vector integration sites near proto-oncogenes after 
drug treatment.  In the dog study, two dogs had to be euthanized due to health 
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complications, but these complications seemed to be unrelated to the MGMT-
transduced cells.  The other non-human primate study (84) did not extensively 
study genome toxicity, but also saw no evidence of clonal dominance or leukemic 
transformation.  MGMT and MDR1 have additionally been combined, with 
bicistronic vectors encoding both genes.  The stoichiometry between the two 
genes has even been examined.  With an MDR1-IRES-MGMT vector, Maier and 
colleagues (86) saw a similar cytoprotective effect for monotherapy with 
paclitaxel or O6-BG/temozolomide, and a greater cytoprotective effect with the 
combination therapy.  Later studies showed that a F2A provided the best 
stoichiometry between the two drug resistant genes for the best cytoprotective 
effect (87).  
Concerns and Genome Toxicity 
 Although lentiviral vectors offer a number of benefits, there are still many 
unmet concerns.  Sustained, high expression is still difficult to achieve, as 
transgene silencing by chromatin modifications is still a problem.  Insulators have 
helped this situation, but it has not been solved entirely.  Additionally, there is a 
mild concern with replication-competent lentivirus; although as generations of 
lentiviruses progress, they resemble the original HIV-1 genome less(88).  The 
SIN, or self-inactivating design for a lentivirus removes a 400bp region from the 
3’ long terminal repeat.  This deletion abolishes the enhancer/promoter activity of 
the virus, therefore reducing transcriptional interference.  It is less likely to 
recombine with cells that have been infected with HIV-1 or make replication-
competent lentivirus as it has less similarity (89).   
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 Several studies have been done on non-viral methods to achieve gene 
transfer (90).  However, these methods have not been as efficient and still have 
difficulty achieving sustained and stable expression.  The Sleeping Beauty 
transposase (SB) system is a non-viral method; it is a synthetic transposon 
system, reverse engineered from defective copies in fish (91).  Sjeklocha and 
coworkers used SB to transduce human CD34+ cord blood cells.  They saw 
integration and expression of the beta-globin gene, and in studies with K562 
cells, saw sustained transgene expression (92).   
 One of the greatest concerns with lentiviral gene therapy is random 
integration.  Random transgene integration can potentially disrupt a tumor 
suppressor or cause activation of an oncogene.  In trials for X-linked severe 
combined immunodeficiency, leukemia developed as a result of aberrant gene 
activation from random integration (93).  One method of preventing malignancy 
with lentiviruses is to analyze the insertion sites before transplantation and select 
those “safe harbor” sites which are least likely to cause endogenous gene 
perturbation.  A safe harbor is an integration site that is more that 50-100 
kilobases away from known coding, miRNA, and ultraconserved regions.  In 
2011, Papapetrou published a paper concerning genomic “safe harbors” and 
induced pluripotent stem cells (iPSCs).  They found that about 10% of 
integrations occurred in safe harbors and permitted beta-globin gene expression 
(94, 95).   
 Another method is to have a failsafe way of getting rid of vector-
transduced cells should they become malignant.  In addition to the therapeutic 
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gene, a suicide gene can also be transduced at the same time.  If malignancy 
occurs, this suicide gene can be induced with drugs to cause apoptosis and 
ablate vector-transduced cells in the body.  Two such suicide genes studied in 
the context of gene therapy are the herepes simplex virus type 1 thymidine 
kinase (HSVtk) and inducible caspase 9 (iCasp9) (96).   HSVtk-transduced cells 
can be eliminated with the phosphorylation of acyclovir or ganciclovir by HSVtk.  
iCasp9 is expressed as a monomer, but upon addition of AP1903, dimerizes and 
causes apoptosis.  In a study with T-cells, iCasp9 effected immediate death, but 
HSVtk needed 3 days of treatment (97).  
 Last, site-specific integration—which does not disrupt other genes—is a 
new area being explored.  Site-specific correction of the beta-globin gene has 
been done with iPSCs.  Making iPSCs from thalassemic cells usually requires 
the addition of four factors:  Oct4, Sox2, Klf4, and c-Myc, although a number of 
other gene combinations have been successfully tried (98, 99).  This field alone 
is a large area of research, and reprogramming can be done in a variety of ways: 
lentiviruses, episomes, nonintegrating viruses, synthetic RNA, or proteins.  In 
2009, Ye and colleagues showed iPSCs could be successfully generated from 
thalassemic patients and upon differentiation, could be stained for HbF (100).  
Zou (101)and Sebastiano (102)showed in two separate papers that thalassemic 
iPSCs could undergo site-specific correction of beta-globin using zinc finger 
nucleases and homologous recombination.  This provided the scientific basis for 
potentially non-integrating in situ correction.  While the iPSCs generated in the 
above papers were done with random integration, it is possible to combine a non-
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integrating method of iPSC generation and site-specific correction, thus avoiding 
integration-associated genome toxicity.  Most recently, Ma in 2013 used non-
integrating episomal technology to create iPSCs and non-integrating TALEN to 
perform in situ correction (103).  All of these studies have been met with very 
limited success though, as iPSCs express extremely low and nowhere near 
therapeutic levels of beta-globin upon differentiation.  Site-specific insertion into 
the adeno-associated virus preferred integration site (AAVS1) has also been 
done with limited success.  In 2008, Howden and colleagues used bacterial 
artificial chromosomes and components from adeno-associated virus to 
preferentially insert beta-globin into the AAVS1 in K562 cells (104).  Of the 36 
insertion sites analyzed, only 6 of them (17%) occurred in AAVS1, and 5 out of 
those 6 were intact and functional.   
Conclusion 
 Beta-globin gene addition strategies have come a long way in the past 25 
years.  Many different vectors with a wide-range of genetic elements have proven 
successful in preclinical tests and some will be tested in clinical trials.  However, 
work still needs to be done to improve the safety and efficacy.  Genomic toxicity 
and malignancy are some of the largest hurdles to overcome in order to move 
gene therapy to widespread clinical application.  Consistently therapeutic 
transgene expression for those with thalassemia major is an additional problem.  
For those vectors that do prove safe and effective, research into increasing the 
number of engraftable lentiviral transduced cells would help with cases of 
insufficient mixed chimerism.  
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At the RNA Level:  Splice Switching Oligos 
Beta-thalassemia is characterized by over 300 mutations.  A subset of these 
mutations creates new cryptic splice sites and, even though the original splice 
sites are intact, leads to incorrect splicing.  The most common splice mutations 
involve the creation of a splice site in intron 1 or intron 2 of the beta-globin gene, 
and are termed IVS1 or IVS2 for intravenous sequence as such.  Specific 
mutations are followed with a number denoting the site of the mutation, such as 
IVS1-110, IVS2-654, or IVS2-745.  Since the correct splice sites are still intact, 
approaches have been made to create splice switching oligonucleotides, which 
cover the aberrant splice site and restore splicing to the original sites.  A splice 
switching oligonucleotide has to achieve a number of goals:  a) it must bind to the 
aberrant splice site and prevent it from being recognized by the splicing 
machinery and b) the duplex it creates must not be recognized by RNaseH, as to 
prevent degradation of the RNA.   
 IVS2-745 is a CG mutation at position 745 within intron 2 that 
generates an aberrant splice site. Aberrant splicing results in the retention of 165 
base pairs of intron 2 in the 745 mRNA, which leads to a missense mutation and 
premature stop codon.  The 745 mutation is relatively common in the 
Mediterranean area, even reaching as high as 15-20% of thalassemia mutations 
in regions of Spain, Jordan, Romania, and Serbia (105). A 745 mutation in a 
homozygous or a compound heterozygous state with other beta-globin mutations 
results in a wide spectrum of phenotypes from non transfusion dependent 
thalassemia (NTDT) to transfusion dependent thalassemia (TDT). Any 
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endogenous increase in hemoglobin production and subsequent reduction in 
transfusions will not only improve the patient’s anemia and co-morbidities, but 
also improve their quality of life.  
Previous studies have shown HbA production in vitro with 2′-O-methyl 
(2’OMe) SSOs on HeLa and 3t3 cells (106).  The 2’-OMe chemistry adds an O-
methyl to the 2’ position of the ribose; it is a naturally occurring RNA modification 
that can be replicated synthetically.  When studies were moved to thalassemic 
patient samples (107), the morpholino chemistry was used, which replaces the 
sugar moieties with morpholine rings.  Morpholino oligos have poor prospects in 
clinical applications alone though, and need to be further chemically modified and 
conjugated a cell-penetrating peptide for successful in vivo delivery (108).  
Subsequent work noted difficulty in uptake for other chemistries to erythroid 
progenitor cells, including the 2’-OMe, 2’-O-methoxyethyl, 2’O-aminopropyl, 
locked nucleic acid, phosphoramidate and methylphosphonate derivative 
chemistries (109).   
Our study was done using the uniform 2’-O-methoxyethyl, or 2’MOE 
chemistry.  The uniform 2’-MOE chemistry adds a methoxyethyl group to the 2’ 
position of the ribose uniformly throughout the SSO.  The substitution contributes 
to an increased stability and binding affinity for RNA.  Uniformly distributed 2’-
MOE SSOs do not mediate RNase H degradation when they bind their targets, 
which may be due to the steric hindrance conferred throughout the oligo by the 
methoxyethyl group.  Safety studies of 2’MOE oligos show they are well tolerated 
in multiple species from rodents to non-human primates; thus, they make an 
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attractive setting for clinical applications (109).  Over thirty compounds are 
currently being tested in clinical trials for various indications including cancer and 
cardiovascular, metabolic, and neurological diseases.  Two examples are 
Mipomersen and Nusinersen:  Mipomersen (marketed as Kynamoro) is a 2’MOE 
antisense oligo that was approved by FDA for the treatment of familial hyper-
cholesterolemia (110).   Nusinersen, a uniformly modified 2’-MOE SSO, is 
currently being investigated in multiple phase 3 clinical trials to treat spinal 
muscular atrophy. Early studies have provided encouraging evidence that 
Nusinersen treatment significantly improved motor neuron function patients 
(111).  
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Chapter Two 
Results:  Adult Hemoglobin Production, Chain Rebalance, and Splice 
Correction in IVS2-745 Beta-thalassemia Patient Cells Using 2’-O-
methoxyethyl Splice-Switching Oligos  
 
In our study we demonstrate that uniform 2’-MOE SSOs are effective in 
treating erythroid cells from thalassemia patients without the requirement of 
additional chemical modification:  they induce both splice switching and HbA 
production.  Furthermore, 2’MOE-SSOs alleviate other previously unstudied 
thalassemic cell parameters, such as a rebalancing of the stoichiometry of alpha 
to beta chains, a reduction of toxic alpha aggregates, and the correction of 
erythrocyte deformities.   
Cell model system 
The 745 allele is a β+ allele: it produces a low level of correctly spliced 
beta-globin mRNA and HbA.  In a study of patients with a 745-sickle genotype 
(112, 113), the single 745 allele contributes only 3-5% HbA in vivo.  For our 
study, we were able to obtain samples from five transfusion-dependent 
thalassemic patients:  four 745/β0 compound heterozygotes (P1-4) and one 
745/745 homozygote (P5).  The compound heterozyogte samples have a non-
functioning secondary allele, termed β0.   β0 alleles by definition do not produce 
HbA, and allow us to fully characterize the potential of the 745 SSO effects.  P1-3 
have a β039 secondary allele and P4 has a IVS1-1 secondary allele. 
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CD34+ cells isolated from patients were expanded, differentiated to the red 
cell lineage, and treated via syringe loading or lipofectamine with 2’-MOE SSOs.  
As seen in the scramble treated controls (Figure 1 and 2), our in vitro model 
system mimics the HbA levels seen in vivo with 745-sickle patients.  Hemoglobin 
HPLC analysis indicated in vitro HbA production in the range of 2.60-6.75%, with 
an average of 4.31 +/- 1.48%.  In all samples, similar results were seen with 
untreated controls (data not shown).   
2’MOE-SSOs induce splice switching 
Three lead 2’-MOE SSOs were raised against the 745 RNA, referred to as 
oligos 91, 92, and 93.  Upon treatment with these oligos, we observed that 
745/β0 heterozygotic patient samples were able to undergo splice reversal at a 
1X dose of 4.5nmoles/1e6 cells (Figure 1A and Supplementary Figure 1).  As 
expected, the scramble treated samples exhibit alternative splicing of beta-
globin:  both the longer 745 alternative mRNA and the shorter WT mRNA are 
present.  Upon treatment, the WT form increases in intensity while the 
alternatively spliced form decreases in intensity.  qPCR results shown in Figure 
1B show the amount of correctly spliced WT beta-globin mRNA increases up to 
100-fold with a 10X dose.  The oligos act with varying levels of effectiveness – 91 
is the most effective, follwed by 92 and 93, respectively.  The oligos also show a 
dose-dependent response:  in the 10X dosed samples, the 745 form is reduced 
beyond detection by gel.   
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Figure 1:  2’MOE SSOs induce splice switching, HbA production, and alpha-
heme tetramer reduction in IVS2-745/β0 heterozygous patient cells.  S=scramble 
control.  All statistics (ANOVA/Kruskal-Wallis) are compared to scramble control 
*p<0.05, **p< 0.01 ***p< 0.001, ****p< 0.0001. [A] PCR for beta-globin cDNA. 
Each lane=single biological sample (full gels see Supplementary Figure 1). [B] 
qPCR for only correctly spliced WT beta-globin mRNA.  Scale indicates relative 
expression as normalized to the housekeeping gene GAPDH and red-cell 
specific gene glycophorin A, n=3. [C] % of HbA and [D] % of alpha-heme 
aggregates from cell lysates as detected by HPLC, n=3. 
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Supplementary Figure 1:  Full gels, including all triplicates, of Figure 1A.   PCR 
for beta-globin on cDNA extracted from patient cells.  The upper band is the 745 
splice mutant form, and the lower band is the WT form. Samples depicted in 
Figure 1A are marked with a “^”. 
 
2’MOE-SSOs restore HbA production in 745 heterozygote patient cells 
The uptick in correctly spliced WT beta-globin mRNA corresponded to a robust 
increase in HbA protein (Figure 1C, Supplementary Figure 2).  With only a 1X 
dose of oligo 91, specimens 1 and 2 increased from their baseline levels of 2.60 
+/- 0.17% and 4.65 +/- 0.46% HbA to 29.21+/- 2.16% and 27.94 +/- 1.09%, 
respectively.  A 5X dose of oligo 91 further increased the level of HbA in 
specimen 2 to 50.83 +/- 0.46%.  At a 10X dose of oligo 91, the dose-dependent 
response was seen again, as specimens 3 and 4 went from baseline levels of 
4.20 +/- 0.75% and 2.97 +/- 0.23% HbA to 59.14 +/- 1.34% and 60.21 +/- 2.61%, 
respectively.  That sums up to a 20-fold increase in HbA in patient 4.  As seen at 
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the RNA level, oligos 92 and 93 were also effective, although the most dramatic 
results were seem with oligo 91.  Oligo 92 induced nearly 50% HbA at a 10X 
dose in both specimens 3 and 4, up to a 16-fold increase.  Oligo 93 induced up to 
43% HbA in specimen 4, a 12-fold increase.   
 
Supplementary Figure 2:  Representative HPLC profile of the separation of 
hemoglobins:  HbA, alpha-heme aggregates, HbF (fetal hemoglobin, a tetramer 
of γ-globin and α-globin), and A2 (hemoglobin A2, a tetramer of δ-globin and α-
globin) 
 
Reduction of alpha-heme aggregates in 745/β0 heterozygote samples 
Due to the imbalance of alpha and beta globin chains in beta-thalassemia, alpha 
and heme aggregates form in the absence of beta chains (114).  These alpha 
aggregates cause a disruption of terminal erythroid differentiation and apoptosis 
of erythroid progenitors (115).  Any reduction in aggregates could help with the 
ineffective erythropoiesis of beta-thalassemia.  Our results demonstrate that the 
increase in HbA in the samples from the heterozygous patients led to a 
concurrent decrease in alpha-heme aggregates (Figure 1D).  The baseline 
aggregate level in heterozygotic cells was variable across samples, with average 
levels ranging from 22.00 +/- 0.76% in P1 to 4.28 +/- 1.12% in P4.  In P1, a 
signficant decrease in aggregates was evident across all oligo treatments, and 
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was most significant in oligo 91 at a 54% reduction.  In P2, a significant reduction 
is seen starting at a 5X dose.  Although baseline levels of aggregates in P3 and 
P4 are lower, oligos 91 and 93 still elicit a significant aggregate reduction at a 
10X dose.  Consistent with our previous observations, oligo 91 was the most 
effective, with as high as an 87% reduction in alpha-heme aggregates in P3. 
  
 
Figure 2:  2’MOE SSOs show the most significant results in homozygous IVS2-
745 patient cells.  S=scramble control.  All statistics (ANOVA/Kruskal-Wallis) are 
compared to scramble control *p<0.05, **p< 0.01 ***p< 0.001, ****p< 0.0001.  [A] 
PCR for beta-globin cDNA. Each lane represents a single biological sample.  [B] 
qPCR for only correctly spliced WT beta-globin mRNA.  Scale indicates relative 
expression as normalized to the housekeeping gene GAPDH and red-cell 
specific gene glycophorin A, n=3. [C] % of HbA and [D] % of alpha-heme 
aggregates from cell lysates as detected by HPLC, n=3. 
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2’MOE SSOs show the most robust effects on a 745/745 homozygote sample 
After demonstrating a dose-dependent response of oligo treatment, we next 
sought to determine if there was also an “allele” dose-dependency, i.e. whether a 
homozygote sample would achieve a higher level of HbA than a heterozygote 
sample.  A homozygote sample produces only 745 mutant pre-mRNA, and thus 
there could be more target 745 pre-mRNA for the oligos to splice switch than in 
the case of a single 745 allele.  Indeed, the homozygous P5 sample baseline 
level of 6.75 +/- 0.22% HbA is higher than in any heterozygous specimen.  This is 
likely due to the additive contribution of the endogenous WT splicing of the two 
745 β+ alleles.  As hypothesized, the most striking effects of oligo treatment are 
seen in the 745 homozygote patient cells (Figure 2).  The 745 mutant form is 
almost undetectable by gel in all treatments; and there is a 300-700 fold increase 
in correctly spliced WT mRNA for the oligo 91 treated samples (Figure 2A-B).  All 
oligos produced their maximum amount of HbA across all patient samples in the 
homozygote sample (Figure 2C).  Oligo 91 produced 79.46 +/- 0.94% HbA at a 
10X dose.  The 20X dose produced similar results with 77.92 +/- 1.04% HbA, 
indicating the effect of this oligo reaches a protein plateau at a 10X dose.  Oligo 
92 and 93 produced 71.42 +/- 1.22% and 58.48 +/- 0.32% HbA at a 10X dose 
respectively.  As with the heterozygote samples, the increase in HbA led to a 
decrease in alpha-heme aggregates in the homozygote as well (Figure 2D).  The 
20X oligo 91 dose in the homozygote led to a 60% reduction in alpha-heme 
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aggregates. 
 
Figure 3:  2’MOE SSO 91 can rebalance the ratio of globins and produce enough 
functional HbA to combat sickling. [A] Single chain analysis of the balance of 
alpha chains to beta-like chains (β, γ, δ) or [B] the ratio of alpha chains to beta 
chains. n=3, scram=scramble treated control at same dose. NS=not significant, 
**p< 0.01, **** p< 0.0001. [C] In vitro sickling assay.  745/Sickle cells were 
treated with scramble or oligo 91, then exposed to hypoxia for sickling.  Barbed 
cells with long polymers of pointy sickle chains are indicated by black arrows.   
 
Rebalancing of the alpha-beta globin stoichiometry 
In order to examine the effects of 2’MOE SSO treatment on the alpha vs beta 
globin stoichimetry, cell lystaes were separated using single-chain protein 
analysis.  This allowed separation of the alpha chains from the beta-like chains 
(β, γ, δ).  Without treatment, the ratio of alpha:beta-like chains ranged from 65:35 
in P1 to 55:45 in P4/P5, all significantly different from a healthy control at 50:50 
(Figure 3A).  Single-chain separation showed though, that at as low as a 5X 
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dose, oligo 91 was able to restore the 50:50 balance of alpha-like chains to beta-
like chains.  Treated samples have no statistical difference compared to a 
healthy control.  Even when examining only alpha-globin and beta-globin (Figure 
3B), the restoration in balance can be seen as the de novo beta-globin is the 
largest contributor.   
 
2’MOE SSOs combat sickling in samples with a 745/sickle genotype 
To address whether the 2’MOE SSOs could induce a functionally relevant 
amount of HbA, we tested their ability to combat sickling in vitro.  As we could not 
obtain a patient sample with the 745/sickle genotype, we created a model 
system:  two homozygous sickle patient specimens (S1 and S2) were transduced 
with a lentivirus expressing IVS2-745 beta-globin.  With vector copy numbers of 
2.02 and 1.62 for S1 and S2, respectively, this system replicated a heterozygotic 
patient sample, as the 2 endogenous sickle alleles were matched.  Upon 
differentiation and exposure to hypoxia, S1 scramble treated cells showed prong-
like polymers of sickle chains.   Oligo 91 treatment of S1 resulted in an increase 
in HbA from 8.96 +/- 1.88% to 59.82 +/- 0.23%, and a decrease in sickle 
hemoglobin (HbS), from 75.34 +/- 2.33% to 30.73 +/- 0.32%.  This increase in 
HbA at the expense of HbS led to 50% reduction in the sickling effect (Figure 
3C).  These results show that 2’MOE SSOs could be indicated for use in 
compound heterozygous 745/sickle patients to reverse RBC deformities. 
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Supplementary Figure 3:  [A] Viability, as assessed by % not stained by Trypan 
Blue and [B] Differentiation, as assessed by the number e6 of benzidine positive 
cells at the end of culture of patient samples. * p<0.05, *** p< 0.001 
(ANOVA/Krunskal-Wallis). 
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Chapter Three 
Methods 
 
Human Ethics   
Patients were recruited and samples obtained according to the Declaration of 
Helsinki, following approvals by the (A) Institutional Ethics Committee of the 
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda 
Ospedale Maggiore Policlinico, Milan, #391/2012 for P1, P2, and P4 (B) Cyprus 
National Bioethics Committee, National Grant ΕΕΒΚ/ΕΠ/2012/05, E.U. Grant 
ΕΕΒΚ/ΕΠ/2013/23 for P3 and P5 and (C) Children’s Hospital of Philadelphia, 
Institutional Review Board (IRB) #5-012123 for S1.  S2 was obtained during 
automated red cell exchange as part of routine clinical care; as S2 was unlinked 
and de-identified medical waste, the Montefiore Medical Center IRB deemed it 
IRB-exempt. 
Statistics 
For three or more groups, we compared means with a one-way ANOVA test (for 
samples with normal distributions and equal variances by the Shapiro-Wilks 
normality test) or medians with a non-parametric Kruskal-Wallis test.  For two 
groups, we compared means with a t-test (for samples with normal distributions 
by the Shapiro-Wilks normality test) or medians with a Mann-Whitney test.  All 
tests were done using GraphPad Prism software, version 7.   
Medias 
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Phase 1:  serum-free StemSpan with 10µL/mL CC-100 cytokine cocktail (both 
from Stemcell Technologies), 2 U/mL Erytrhopoietin (Amgen), 10−6 M 
dexamethasone (Sigma) and 1% penicillin streptomycin.  Freeze Media:  50% 
characterized FBS (Hyclone), 10% DMSO (Sigma), and 40% Iscove’s Modified 
DMEM(Cellgro).  Thaw Media:   Iscove’s Modified DMEM with 5% characterized 
FBS.  Phase 2:  Iscove’s Modified DMEM with 3% AB serum (Atlanta 
Biologicals), 2% Human Plasma (Stemcell Tech), 10ug/mL Insulin (Sigma), 
3U/mL Heparin, 200ug/mL Transferrin (Athens Research & Technology), 
10ng/mL SCF (Peprotech), 3U/mL EPO (Amgen).  Phase III media:  same as 
Phase II, but with 1mg/mL transferrin. 
Cell Culture 
Whole blood underwent CD34+ selection using immunomagnetic separation 
(Miltenyi Biotec Inc., Auburn, CA).  CD34+ cells were kept undifferentiated in 
phase 1 media with bi- or tri-weekly media changes, centrifugation to remove 
both dead and spontaneously differentiating cells and by keeping cell density 
<0.5e6 cells/mL,.  After 8-10 days, cells were frozen in freeze media.  Cells were 
thawed in thaw media, centrifuged 10’ at 200g to remove dead cells, and 
resuspended in phase I.  After 12 total days in phase I, cells were transferred into 
phase II media or a 2:1 mix of phase I and phase III media.  SSO treatment 
occurred on day 14 using 1-2e6 cells/condition; 1X dose was 4.5nmoles/1e6 
cells.  For syringe loading, cells were resuspended at 1e6/100µL, passed 10 
times through a 25 gauge needle, then kept at for 1 hr at 37ºC.  Lipofectamine 
(ThermoFisher) was used according to the manufacturer’s protocol, with 150µL 
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Opti-MEM (ThermoFisher) and 6µL lipofectamine/1e6 cells.  Following SSO 
treatment, cells were plated at 1e6 cells/mL in phase III media.  Collection 
occurred on day 20 for all analyses. Toxicity was assessed by trypan blue 
staining and level of differentiation was assessed by benzidine staining (116).   
RNA, PCR, and real-time qPCR 
Total RNA was isolated using Trizol (ThermoFisher).  Retrotranscription of total 
mRNA was done using the SuperScript™ III First Strand Kit (ThermoFisher). 
PCR reactions were performed with the following primers:Fw: 5′-
GGCAAGGTGAACGTGGATGAAGTT -3′; Rev: 5′-
TAGGCAGAATCCAGATGCTCAAGG-3′.  q-PCR reactions were performed 
using the ABI 7900HT or Viia7 systems (Applied Biosystems), with either 
TaqMan (TaqMan PCR 2X Master Mix from ThermoFisher) or SYBR Green 
(Power SYBR from ThermoFisher or iTaqTM SYBR® Green Supermix from Bio-
Rad) chemistry. Quantitative real-time PCR assays of globin, GAPDH, and 
glycophorin A transcripts were carried out using gene-specific double 
fluorescently labeled probes. The following primer and probe sequences were 
used (forward, reverse and probe, when used, of each gene, respectively): WT 
correctly spliced beta-globin primers=Fw: 5′-CACCTTTGCCACACTGAGTGA-3′; 
Rev: 5′-GCCCAG GAGCCTGAAGTTCT-3′; 5′-FAM-
CACTGTGACAAGCTGCACGTGGATCC-IOWA BLACK-3.  The following 
TaqMan inventoried Gene Expression assays from Thermo Fisher were used:  
GAPDH:  Hs02758991_g1; GYPA:  Hs00266777_m1.  qPCR results of WT beta-
globin were normalized by GAPDH to control for the total amount of cDNA and 
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GYPA to control for the level of differentiation across samples.  For PCR of 
human beta-globin cDNA, the following primers were used:  Fwd 5’-
GTGCGAGAGCGTCAGTATTAAG-3’, Rev 5’-TCCCTGCTTGCCCATACTA-3’.   
Tetrameric and single chain analysis by high performance liquid chromatography 
(HPLC). 
Cell pellets were disrupted with Cytobuster (EMD Millipore) for single chain 
analysis and water for tetramer analysis.  For tetrameric analysis supernatant 
hemolysates were loaded into a System Gold 126 Solvent Module instrument 
(Beckman Coulter). Hbs were separated on a weak cation-exchange PolyCAT A 
column (PolyLC), and detected at a wavelength of 415 nm. The Hbs were bound 
to the column with mobile phase A (20 mmol/L Bis-Tris, 2 mmol/L KCN, pH 6.96) 
and eluted with mobile phase B (20 mmoI/L Bis-Tris, 2 mmol/L KCN, 200mmol/L 
NaCl, pH 6.55). Single chain quantification was assessed by reverse-phase 
HPLC. Hb samples were injected on a Hitachi D-7000 HSM Series apparatus 
(Hitachi Instruments) using a Zorbax 5 µm 300SB-C8 300 Å, LC 150 x 2.1 mm 
column (Agilent Technologies) and a gradient from 20% to 60% acetonitrile in 
0.1% trifluoroacetic acid in 25 minutes, with UV detection at 215 nm. Standards 
of HbA, HbF, HbS, and HbC were injected (Analytical Control Systems) and used 
to determine various Hb peak types (116). 
Vector production and Titering  
The WT beta-globin coding sequence from the vector AnkCT9W [Breda 2012] 
was mutagenized to the IVS2-745 beta-globin sequence, creating AnkCT9W-
745.  Viral stocks were generated by co-transfection of AnkCT9W-745 plasmid 
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together with the envelope plasmid (VSV-G), the packaging plasmid (pMDLg/p 
RRE), and the pRSV-REV plasmid into 293T cells (38). An aliquot (5×106) of 
293T cells was seeded into cell culture dishes (10 cm) 24 hours prior to 
transfection in Iscove's modification of Eagle's medium (DMEM, Cellgro, 
Manassas, VA) with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml 
streptomycin, at 37°C under 5% CO2. The culture medium was changed 2 hours 
prior to transfection. The precipitate was formed by adding the plasmids to 450 
uL of 0.1× TE (0.1× TE is 10 mM Tris plus 1 mM EDTA) and 50 µL of 2 M CaCl2, 
then adding 500 µL of 2× HEPES-buffered saline (281 mM NaCl, 100 mM 
HEPES, 1.5 mM Na2HPO4) drop wise after which the precipitate was vortexed 
and immediately added to the cultures. The medium (10 ml) was replaced after 
16 hours. Viral supernatants were collected at 24 and 48 hours, cleared by low 
speed centrifugation, and filtered through cellulose acetate (0.2 µm). Following 
ultracentrifugation, serial dilutions of concentrated virus (5; 0.5 and 0.05 µL, 
respectively) were used to infect 1×105 NIH 3T3 cells (ATCC, Manassas, VA) in 
1 mL of transfection buffer complemented with polybrene (Millipore, Billerica, MA) 
at a final concentration of 8 µg/mL. Genomic DNA was extracted after 3 days 
using phenol-chloroform-isoamylic alcohol. The multiplicity of infection (MOI) was 
calculated using the following formula: number of cells (1×105) X dilution factor (1 
mL/µL viral preparation) X VCN (measured via real-time PCR, using oligos for 
WPRE element and Transferrin Receptor gene, see copy number determination) 
(117).   
In vitro RBC sickling and morphological analysis 
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CD34+ cells were transduced with in expansion (phase I media).  2-3 days later, 
cells were put in phase II media and genomic DNA was extracted.  Copy number 
was determined as below.  SSO treatment with 10X scramble or 10X 91 oligo 
occurred 2-3 days after the start of phase II; cells were then placed for 6 days in 
phase III before harvest.  We assessed the degree of cell sickling in our 
experimental samples using previously reported methodology, with slight 
modifications (117). Briefly, 0.5 - 1 million cells were suspended in isotonic 
Hemox buffer (TCS Scientific Corp, Southampton, PA), pH 7.4, supplemented 
with 10 mM glucose and 0.2% bovine serum albumin, in individual wells of a 
Costar polystyrene 96-well microplate (№ 9017; Corning, Corning, NY). The 
microplate was then transferred to a Thermomixer R shaker-incubator 
(Eppendorf), and maintained under hypoxia (Nitrogen gas), with continuous 
agitation at 500 rpm, at 37° C for 2 hours. At conclusion, aliquots of each sample 
were collected in 2% glutaraldehyde solution for immediate fixation without 
exposure to air.  Subsequently, fixed cell suspensions were introduced into 
specialized glass microslides (Dawn Scientific, Inc., Newark, NJ) (118) for 
acquisition of bright field images (at 40x magnification) of single layer cells on an 
Olympus BX40 microscope fitted with an Infinity Lite B camera (Olympus) and 
the coupled  Image Capture software. 
Copy Number Determination 
The number of integrations (VCN) was quantified by Q-PCR using oligos for (Fw: 
5’-GTGCGAGAGCGTCAGTATTAAG-3’; Rev: 5’-TCCCTGCTTGCCCATACTA-
3’) for a specific sequence present in the vector (GAG) and compared it to an 
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endogenous control present in two copies within the genome (mouse 
Transferrin=Fw: 5’-TGTTGTAGTAGGAGCCCAGAGAGA-3’; Rev:5’-
AGACCTGTTCCCACACTGGACTT-3’; human ID-1=Fw: 5′-
AAGGTGAGCAAGGTGGAGATTC-3′; Rev: 5′-TTCCGAGTTCAGCTCCAACTG-
3′). 
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Chapter Four 
Discussion and Future Perspectives 
 
2’MOE SSOs have strong therapuetic potential for splice mutants of beta-
thalassemia.  They effectively correct at the RNA level where the defect occurs, 
and lead to correction of the thalassemic cell phenotype.  The novel production of 
beta-globin chain leads to HbA production, a coincinding rebalancing of the alpha 
and beta chains, and a reduction in alpha heme aggregates.  As demonstrated 
by the sickle assay, the oligos even produce enough total HbA to have true 
functional relevance. 
When extrapolating on the clinical potential of 2’MOE SSOs in vivo, we 
can examine the data of two previously reported patients with a 745/sickle 
genotype (112). These patients expressed 4.8% HbA and their combined 
HbA/HbF/HbS levels average 8.6g/dL.  If we take these numbers into account, 
0.41g/dL of this patient is HbA from the correctly spliced single endogenous 745 
allele.  2’MOE SSOs are able to induce up to a 20-fold increase in HbA 
compared to control – this would translate to over an 8 g/dL increase.  As 9g/dL 
is transufsion-independent, these oligos could very feasibly help pateints achieve 
transfusion independence.  Transfusion independence is a key achievement 
factor, as transfusion is a contributing factor to iron overload and mutliple organ 
damage (4).   
This is of course contingent on toxicity studies and drug delivery studies.  
As previously stated, 2’MOE show a favorable tolerability (119).  We observed no 
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significant difference in viability or differentiation for almost all our of treatments 
(Supplementary Figure 2).  If we were to look toward the future though, a side-
by-side study would need to be done on multiple patient samples across the 
doses.  For our study, the 1X and 5X dose were used on the same patient and 
produced no significant differences.  However, the 10X and 20X dose were 
tested on different patient samples.  As these samples were harvested from 
different patients, at separate timepoints, by different collaborators, and shipped 
separately, we cannot make a true side-by-side comparision.  The limited by the 
availability of donor material and skilled researchers to collect this material 
prevents us from executing this fully, but better access to local patient databases 
or training more collaborators could allow such a large-scale study.  
Another barrier to clinical translation is the ability to target the oligo to the 
bone marrow, as 2’MOE oligos accumulate the most in the kidney and liver 
(120).  The spleen though, is the 3rd highest accumluation area, with 
concentrations between 20-50% of that in the liver.  The distribution within the 
spleen by cell type has not been well characterized, but data shows the most 
accumulation in the macrophages (119).  2’MOEs need physical or chemical 
manipluation to enter cultured cells.  However in vivo and some primary cell 
cultures studies show natural cellular uptake pathways without this manipulation 
(119).  Of course, in vitro systems do not always mimic in vivo systems, but as a 
future indication we could co-culture macrophages with our erythroid progentors 
to determine if the macrophages are preventing oligo uptake.  Per in vivo, the 
lack of an appropriate human 745 beta-globin mouse model prevented us from 
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fully executing these studies at this time, but other in vivo rodent studies show 
promise.  Recent data suggests that the constrained ethyl (cEt) chemistry in 
antisense studies is successful at targeting the rat and mouse bone marrow 
(121).  The 2’MOE chemistry can potentially be combined with the cEt chemistry 
for better in vivo delivery.  Nonetheless, a conjugated strategy that can direct 
SSO uptake by erythroid cells would be ideal.  The oligo can potentially be 
conjugated to a protein that has an affinity for erythroid progenitors or the bone 
marrow to achieve specific targeting.   
In summary, 2’MOE-SSOs are promising therapeutic tools for certain 
splicing forms of beta-thalassemia.  Their ability to correct the underlying splicing 
defect offers a pharmacological treatment that is both direct and specific.  As 
such, this therapy could help patients reduce their transfusion dependence or 
even reach transfusion independence.   
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Appendix:  ALS10, a new gene therapy vector 
 
*Authorship Note: This work was filed for patent under PCT patent publication 
number WO 2016118715, with Stefano Rivella, Laura Breda, Gerd Blobel, and 
Wulan Deng.  This work has been moderately reformatted for this thesis, but 
remains in the general formatting style of the patent application.   
 
VIRAL VECTORS FOR PROPHYLAXIS AND THERAPY OF 
HEMOGLOBINOPATHIES 
 
CROSS REFERENCE TO RELATED APPLICATIONS 
This application claims priority to U.S. Provisional application no. 62/105,829, 
filed on January 21, 2015, the disclosure of which is incorporated herein by 
reference.  
 
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH 
This invention was made with government support under contract no. 
1R01HL102449 awarded by the National Institutes of Health. The government 
has certain rights in the invention. 
 
FIELD  
The present disclosure related to compositions and methods useful for 
prophylaxis and/or therapy of hemoglobinopathies. 
 
ABSTRACT 
Provided are compositions and methods for inducing expression of human beta-
globin in erythrocytes for use in prophylaxis and/or therapy of a 
hemoglobinopathy in an individual.  The method generally entails introducing into 
CD34+ cells a polynucleotide encoding: i) a 5’ long terminal repeat (LTR) and a 
self-inactivating 3’ LTR; ii) at least one polyadenylation signal; iii) at least one 
promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator 
element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured 
such that the WPRE does not integrate into a target genome; and vii) a sequence 
that is a reverse complement of a sequence encoding human beta-globin, and 
can include beta-globin that has a βT87Q mutation.  Intron 2 of the beta globin 
gene can be a complete intron.  Modified erythrocyte progenitor cells, 
recombinant vectors and virions comprising recombinant polynucleotides, and 
methods of making the vectors and virions are included. 
 
BACKGROUND  
There are a variety of hemoglobinopathies that affect large portions of the human 
population.  For example, sickle-cell anemia (SCA) is a blood related disorder 
that affects the structure of the hemoglobin molecules. In SCA the hemoglobin 
molecule is defective, causing the entire blood cell to change shape (122).  After 
these abnormal hemoglobin molecules release oxygen in circulation, they may 
cluster together and form long, rod-like structures, which become rigid and 
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assume sickle shape. Unlike healthy red blood cells, which are usually smooth 
and donut-shaped, sickled red blood cells cannot squeeze through small blood 
vessels. Instead, they stack up and cause blockages that deprive organs and 
tissues of oxygen-carrying blood. This produces periodic episodes of pain and 
ultimately can damage tissues and vital organs and lead to other serious medical 
problems. Normal red blood cells live about 120 days in the bloodstream, but 
sickled red cells die after about 10 to 20 days. Because they cannot be replaced 
fast enough, the blood is chronically short of red blood cells, leading to anemia. 
SCA affects millions throughout the world. It is particularly common among 
people whose ancestors come from Sub-Saharan Africa, South America, Cuba, 
Central America, Saudi Arabia, India, and Mediterranean countries such as 
Turkey, Greece, and Italy. In the Unites States, it affects around 72,000 people, 
most of whose ancestors come from Africa. The disease occurs in about 1 in 
every 500 African-American births and 1 in every 1000 to 1400 Hispanic-
American births. About 2 million Americans, or 1 in 12 African Americans, carry 
the sickle cell allele. 
Beta-thalassemia is one of the two the most common congenital anemias and is 
due to partial or complete lack of synthesis of beta-globin chains and 
hemoglobin. Patients affected by beta-thalassemia have mutations in the beta-
globin gene. The World Health Organization (WHO) estimates that 50,000 to 
100,000 children are born with symptomatic features of beta-thalassemia every 
year. Cooley’s anemia, also known as beta-thalassemia major, the most severe 
form of this disease, is characterized by ineffective erythropoiesis (IE) and extra 
medullary hematopoiesis (EMH) requiring regular blood transfusions to sustain 
life.   
In beta-thalassemia intermedia, where a greater number of beta-globin chains 
are synthesized, the clinical picture is milder and patients do not require frequent 
transfusions (Musallam, K.M., et al. Non-transfusion-dependent thalassemias. 
Haematologica 98, 833-844 (2013); Rivella, S. The role of ineffective 
erythropoiesis in non-transfusion-dependent thalassemia. Blood reviews 26 
Suppl 1, S12-15 (2012); Ginzburg, Y. & Rivella, S. beta-thalassemia: a model for 
elucidating the dynamic regulation of ineffective erythropoiesis and iron 
metabolism. Blood 118, 4321-4330 (2011)). However, hemoglobin levels often 
decrease over time, splenomegaly appears, and patients suffer from progressive 
iron overload due to increased gastrointestinal iron absorption. Current disease 
management includes prenatal diagnosis, transfusion therapy, iron chelation and 
allogeneic bone marrow transplantation (BMT), which is limited by finding a 
compatible bone marrow donor and presents many risks and complications. 
Beta-thalassemia or Cooley’s anemia has a serious impact on the life of those 
afflicted, as well as on society in general. Therefore, potential gene therapy 
approaches that provide therapy to these patients would be highly relevant.  In 
this regard, mutations leading to Cooley's anemia can be classified as beta0, 
such as beta0-39, in which a single point mutation creates a stop codon and no 
beta-globin protein is produced, or beta+, such as beta+-IVS1-110, where a 
mutation in the first intron results in alternative splicing and insufficient beta-
globin chain synthesis (Musallam, K.M., et al. Non-transfusion-dependent 
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thalassemias. Haematologica 98, 833-844 (2013); Rivella, S. The role of 
ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood 
reviews 26 Suppl 1, S12-15 (2012); Ginzburg, Y. & Rivella, S. beta-thalassemia: 
a model for elucidating the dynamic regulation of ineffective erythropoiesis and 
iron metabolism. Blood 118, 4321-4330 (2011)). Previous research has shown 
that it is possible to rescue beta-thalassemia in mouse models by lentiviral-
mediated beta-globin gene transfer (May, C., et al. Successful treatment of 
murine beta-thalassemia intermedia by transfer of the human beta-globin gene. 
Blood 99, 1902-1908. (2002); May, C., et al. Therapeutic hemoglobin synthesis in 
beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. 
Nature 406, 82-86 (2000); Rivella, S., et al. A novel murine model of Cooley 
anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. 
Blood 101, 2932-2939 (2003)).  However, these animals are characterized by a 
complete deletion of the mouse beta-globin gene. Additional hemoglobinopathies 
are characterized by mutations in the beta-globin gene that lead to additional 
aberrant beta-globin chains and patho-physiological sequelae similar to sickle 
cell anemia and/or beta-thalassemia.   Thus, there is an ongoing and unmet need 
for improved compositions and methods for treating hemoglobinopathies.  The 
present disclosure is pertinent to this need. 
 
SUMMARY  
The present disclosure provides compositions and methods for prophylaxis 
and/or therapy of hemoglobinopathies.  In general, hemoglobinopathies comprise 
disorders that are characterized by reduced synthesis or abnormal structure of 
the hemoglobin molecule.  Thalassemias are considered a type of 
hemoglobinopathy, with the understanding that certain forms of 
hemoglobinopathies are typically inherited single-gene disorders that result in 
abnormal structure of one of the globin chains of the hemoglobin molecule, 
whereas thalassemias are considered other forms of hemoglobinopathies 
associated with underproduction of normal globin proteins, such as those cases 
that arise due to mutations in regulatory genes.  Thus, the disclosure is pertinent 
to individuals in need of treatment for disorders that include but are not 
necessarily limited to those characterized by altered hemoglobin structure, such 
as in hemoglobin C disease, hemoglobin S-C disease, sickle cell anemia, as well 
as in various types of thalassemia that are well known in the art, including but not 
necessarily limited to beta-thalassemia. This is also pertinent to patients that 
have mixed hemoglobinopathy features, such as hemoglobin S/thalassemia, for 
instance.  
In one aspect the disclosure provides a method for inducing expression of human 
beta-globin in erythrocytes for use in prophylaxis and/or therapy of a 
hemoglobinopathy in an individual.  The method generally comprises introducing 
into erythrocyte progenitor cells, typically CD34+ cells, a polynucleotide 
encoding: i) a 5’ long terminal repeat (LTR) and a self-inactivating 3’ LTR (self-
inactivating meaning the 3’ LTR comprises a deletion relative to its native 
sequence, and thus results is replication incompetent); ii) at least one 
polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control 
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region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-
Regulatory Element (WPRE) configured such that the WPRE does not integrate 
into a target genome; and vii) a sequence that is a reverse complement to a 
sequence encoding modified human beta-globin comprising a βT87Q mutation 
(B-globinM).  The sequence of human B-globinM is included with this disclosure.  
The B-globinM is expressed from integrated DNA that is derived from the viral 
genome.  Thus, the B-globinM sequence in the RNA genome of the modified 
lentiviral vectors of this disclosure is configured so that  the B-globinM is 
expressed in the context of the double stranded DNA that is from integration of 
the modified lentiviral genome.   The expression can in certain embodiments be 
exclusive to certain cell types, such as erythrocytes.   It will be recognized in 
certain instances that DNA sequences are provided, but those skilled in the art 
can readily envision the RNA equivalent of the DNA sequence, such as when a 
DNA sequence is used to illustrate features of a lentiviral genome. 
The sequence encoding the B-globinM comprises a first intron (intron 1) between 
exon 1 and exon 2, and a second intron (intron 2) between exon 2 and exon 3.  
In certain embodiments intron 2 comprises more than 476 nucleotides of the 
human B-globinM intron 2 sequence, and may comprise up to the full intron 2 
sequence.  After introducing the lentiviral construct into erythrocyte progenitor 
cells the lentiviral construct integrates into one or more chromosomes in the 
progenitor cells, and the progenitor cells differentiate into erythrocytes.  The 
erythrocytes derived from the erythrocyte progenitor cells produce the beta-
globin protein.   
The disclosure provides for modified erythrocytes that produce more human 
beta-globin than a suitable control.  In one embodiment the control comprises a 
human beta-globin value obtained from control cells.  In one non-limiting 
approach the control cells comprise erythrocytes from an individual who has the 
hemoglobinopathy, wherein the erythrocytes are progeny of progenitor cells into 
which a control viral vector was introduced.  The control viral vector can 
comprise, for example, the 5’ LTR, the 3’ LTR, the at least one polyadenylation 
signal, the at least one promoter, the LCR, the Ank, a WPRE, and the sequence 
encoding the B-globinM, but the sequence encoding the B-globinM in the control 
viral vector comprises 476 or fewer nucleotides of the human B-globinM intron 2 
sequence, and thus comprises an intron 2 that contains a deletion.   In one 
embodiment, the modified erythrocytes produce increased adult hemoglobin, 
fetal hemoglobin, B-globinM, or a combination thereof, relative to a control.   
In one embodiment the lentiviral vectors can further comprise a sequence 
encoding a fusion of an Ldb1 transcription factor and a zinc finger (ZF) domain.  
In certain embodiments the lentiviral vector can comprise a sequence encoding 
an RNA polynucleotide that is at has reverse complementarity to mRNA 
encoding transferrin receptor 1.  The RNA polynucleotide is capable of 
decreasing transferrin receptor 1 mRNA by, for example, an RNAi-mediated 
process.   
In certain approaches the disclosure includes modifying erythrocyte progenitor 
cells that are CD34+ cells.  The CD34+ cells can be separated from the 
individual before the lentiviral vector is introduced into them.  The CD34+ cells 
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can be introduced into the individual subsequent to the introduction of the 
lentiviral vector.  The lentiviral vector can be introduced using any suitable 
approach. In one embodiment the erythrocyte progenitor cells are infected with 
viral particles comprising a lentiviral vector, such as a recombinant + strand viral 
polynucleotide.  In certain embodiments, approximately 50 infection particles (IP) 
per cell are used.  In certain embodiments the cells into which the vector is 
introduced can be enriched for a certain cell type, such as CD34+ cells. In certain 
approaches the cells are held for a period of from 2-3 days after infection prior to 
introducing into an individual in need thereof.  In embodiments the cells can be 
frozen and introduced into the patients after they are thawed.  The lentiviral 
vectors can be introduced into a patient using any suitable method.  In one 
approach they are administered by intravenous infusion, which may be 
performed subsequent to any other technique, such as after depletion of bone 
marrow cells, i.e., myeloablation.  Those skilled in the art will recognize that a 
cells characterized by a suitable vector copy number (VCN) can be used.  In one 
embodiment the VCN is approximately 1 VCN per cell.   
The disclosure includes the lentiviral vectors themselves, the components of 
which are as described above for use in a method of the disclosure.  Lentiviral 
vectors comprise modified, recombinant polynucleotides, and can comprise RNA 
or DNA polynucleotides.  In certain embodiments a lentiviral vector of this 
disclosure comprises an isolated polynucleotide, or an isolated preparation of 
virions that comprise the lentiviral vector.  In an embodiment a recombinant 
lentiviral vector of the disclosure is present in CD34+ cells, wherein the CD34+ 
cells have been separated from an individual.  
Also provided is a method of making a viral particle preparation for use in 
prophylaxis and/or therapy for one or more hemoglobinopathies.  This approach 
comprises introducing a plasmid encoding a lentiviral vector as described above 
into packaging cells, wherein the packaging cells comprise a DNA packaging 
plasmid which encodes at least one virion protein, and wherein the packaging 
cells comprises a DNA envelope plasmid which encodes an envelope protein.  
The packaging and envelope plasmids express their respective proteins, which 
facilitate formation of virions which comprise an RNA lentiviral vector of this 
disclosure. 
 
DESCRIPTION OF THE FIGURES 
Figure 1. The level of HbF/GFP expressing cells increases proportionally to the 
amount of molecules of GG1-SA vector integrated. (A) Lentiviral construct 
carrying the bicistronic cassette that expresses the Ldb1 SA domain under the 
ankyrin promoter (Ank Pr.) and the green fluorescence protein (GFP) through an 
internal ribosomal entry site (IRES). The Woodchuck hepatitis virus 
Posttrascriptional Regulatory Element (WPRE) increases RNA stability and 
protein yield. (B) Percentage of F, S and A2 hemoglobins measured by HPLC in 
differentiated untreated erythroid cells (left) or with up to 0.7 copies of ZF-Ldb1-
viral molecules integrated on average (middle and right). (C) Increase in HbF and 
(D) GFP expressing cells measured by flow cytometry in cells untreated or with 
0.26 and 0.67copies/cell of ZF-Ldb1-viral molecules integrated.   
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Figure 2. pCL-ZF-Ldb1 supports high levels of γ-globin/hemoglobin F induction 
and concurrently reduces sickle globin levels in sickle cell disease (SCD) 
erythroblasts. (A) β-like globin mRNA content (γ, left, and βs, middle) was 
measured by Q-PCR and normalized by endogenous GAPDH expression. β-like 
globin expression changes were further normalized by α-globin expression 
(which should remain unchanged and is a measure of differentiation across 
samples). Right: transgenic ZF-Ldb1 mRNA expression in treated samples is 
plotted against integration of pCL-ZF-Ldb1. (B) HbF (left), HbS (middle) and 
HbA2 (right) changes in all SCD samples treated with pCL-ZF-Ldb1 LV. (C) Net 
HbF% increase and HbS%-A2% decrease. 
 
Figure 3. Quantification of tetrameric Hbs and single globin chains in SCD cells 
untreated and treated with pCL-ZF-Ldb1. (A) Content of HbF increase (left) and 
all Hbs (right) in erythroid cells without or with pCL-ZF-Ldb1. (B) Single globin 
quantification by liquid chromatography in denaturing conditions. On left, the 
quantity of single β- and γ-globin chains (μg) is calculated over the quantity of 
single α- globin chain. On right, means of γA+G chains/all β-like chains area 
indicated. μg of Hbs or single globin chains in hemolysates were extrapolated 
from calibration curves obtained with standard samples with known Hb 
concentration. 
 
Figure 4. pCL-ZF-Ldb1-transduced SCD cells expressing HbF have a reduced 
expression of HbS compared to untransduced cells. (A) The number of GFP 
expressing SCD erythroblasts after pCL-ZF-Ldb1 integration (right) is compared 
to untransduced erythroblast (left). (B) Percentage of HbF producing cells in 
permeabilized erythroblasts (left, no anti-HbF Ab), untransduced (center) and 
pCL-ZF-Ldb1 transduced erythroblasts (right). (C) β-globin expressing cells 
within the HbF positive populations from B (center and right) are compared to 
permeabilized cells (left, no anti-HbB Ab). (D) quantification of HbF of SCD 
samples (from B) analyzed by HPLC. 
 
Figure 5. Expression of γ-globin repressor genes in healthy cells, sickle cells 
untreated or treated with pCL-ZF-Ldb1 LV. (A) Bcl11A, C-Myb, (B) SOX6 and 
KLF1 genes’ expression is expressed in function of the level of cell differentiation 
marker glycophorin A (GPA) and normalized by GAPDH expression. The 
expression of KEL (C, left), the gene that encodes Kell, a blood group antigen, 
was chosen as internal control. Expression of transgenic Ldb1 in transduced 
samples (C, right) was confirmed in the same samples analyzed for the other 
messenger RNAs. 
 
Figure 6. Hemoglobin F increase/ Sickle hemoglobin decrease in CD34+-derived 
SCD erythroid cells treated with pCL-ZF-Ldb1 LV and with HbF inducers in vitro. 
(A) (Top) Net increase of HbF% and (bottom) net decrease of HbS% in SCD 
erythroblasts treated with the HbF inducers decitabine, tranylcypromine, 
hydroxyurea, pomalidomide, butyrate or with the LV carrying ZF-Ldb1. (B) 
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Erythroid cell count (hemoglobinized cells, or benzidine+ stained cells) for each 
treatment is been normalized over the untreated sample. In A-B n=11, except for 
Hu and pCL-ZF-Ldb1 in which n=10, while for But n=9. 
 
Figure 7. Differential single globin chain synthesis in cells treated with pCL-ZF-
Ldb1. (A) Chromatographic profile of representative sickle cells hemolysate 
untreated (UT) or treated with pCL-ZF-Ldb1. (B) Calibration curve obtained using 
known hemoglobin concentration of blood from SCD transgenic mouse. (C) 
Areas under peak of single globin chains extrapolated from the calibration curve 
(from B) in samples untreated or after treatment with pCL-ZF-Ldb1 (n=5).  
 
Figure 8. Trend of moderately elevated HbF levels in CD34+-derived SCD 
erythroid cells at steady state. Comparative HPLC assessment of HbF% between 
healthy and SCD erythroid samples in which γ-globin repressors BCl11a, c-Myb, 
KLF1 and SOX6 were quantified 
 
Figure 9. Cytotoxicity effect and dose/response calibration. Erythroid cells count 
measurements (benzidine plus count) of cells (N=2) at different doses of drugs in 
comparison with integration of ~1 copy/cell of GG1-SA. The arrows in black 
indicate the dose of each drug chosen for the bulk of the experiments. 
 
Figure 10. Variation of HbF% SCD erythroid cells treated with pCL-ZF-Ldb1 
vector and with HbF inducers in vitro at different times. Net increase of HbF% in 
SCD erythroblasts treated with the HbF inducers 5-aza-cytidine or with the LV 
carrying ZF-Ldb1, according to tables 1 (L) and S1 (E). Kruskal-Wallis with 
Dunn’s multiple comparison test. 
 
Figure 11.  Graphical maps of vectors.  Topmost vector map is pCL-ZF-Ldb1, 
also referred to as pCL20cAnkyrinGG1DDiGFP.  Second from vector map is 
ALS-10.  Third from top vector map is CT9Ank.  Bottom vector map is ALS-10T. 
Each vector comprises a 5’ and a 3’ self-inactivating long terminal repeat (5’LTR 
and 3’SinLTR, respectively). Also shown is “B-globinM” which is a mutant beta-
globin is known as the “βT87Q” form. The B-globinM is configured in the vector 
such that it is expressed from an integrated DNA that is derived from the RNA 
genome via a well-known process.  “Ank” is an Ankyrin insulator. “IRES” is an 
internal ribosomal entry site. “P” designates a promoter. “LCR” is a Locus control 
region. “GFP” is enhanced green fluorescence protein. “pA” is a polyadenylation 
signal. “WPRE” is the Woodchuck Post-Regulatory Element. “fI1” is a full beta-
globin gene intron 1. “fI2” is a full beta-globin gene intron 2. “I1S” is a modified 
beta-globin gene intron 1 comprising a microRNA targeting the transferrin 
receptor. “SV40 oriR-pA” is an origin of replication and polyadenylation signal.   
Beta-globin gene exons 1, 2 and 3 are labeled accordingly.   
 
Figure 12 provides a graphical summary of results comparing adult hemoglobin 
values (HbA) obtained from β0/+ or β0/0 erythroblasts patient CD34+ cells into 
which the AnkT9W and ALS10 vectors were introduced, as labeled. 
67 
 
 
Figure 13 provides an annotated polynucleotide and encoded protein sequence 
of the ZF-Ldb1 vector and the DNA equivalent of the RNA.  The nucleotide 
sequence in Figure 13 is SEQ ID NO:1.  The ZF-LDB1 AA sequence (shown as 
GG1=ZF and DDi=LDB1, with the HA terminal amino acid sequence) is SEQ ID 
NO:2.  Vector features labeled in boxes are shown above the pertinent 
sequences.   
 
Figure 14 provides an annotated polynucleotide sequence of the ALS-10 vector 
as the DNA equivalent of the RNA and encoded protein sequence.  The 
nucleotide sequence shown in Figure 14 is provided as SEQ ID NO:3.  Vector 
features in boxes are shown above the pertinent sequences.  The location of the 
initiating βT87Q beta globin methionine codon in its antiparallel configuration is 
the “CAT” triplet to the immediate left of the beta globin 5’ UTR, reading in the 5’ 
to 3’ direction.   
 
Figure 15 provides an annotated sequence of the non-mutated beta-globin 
cDNA.  The cDNA sequence is SEQ ID NO:4.  Also shown is the beta-globin 
amino acid sequence which is provided in SEQ ID NO:5.  The βT87Q mutation 
occurs at the Threonine which is shown in the sequence at position 88.  The 
mutation is referred to as βT87Q according to convention wherein the first 
Methionine at position 1 is not included in the amino acid numbering.  In the 
βT87Q mRNA, the codon for the Threonine at position 88 is replaced by a codon 
encoding Glutamine.   
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DETAILED DESCRIPTION  
The present disclosure provides compositions and methods for 
prophylaxis and/or therapy for hemoglobinopathies.  In this regard, and as is well 
known in the art, a few months after birth children start producing red cells 
containing adult hemoglobin, which is the oxygen carrier molecule made of 
alpha- and beta-globin chains, encoded, respectively, by the alpha- and beta-
globin genes. In many hemoglobinopathies, mutations in the gene encoding the 
beta-globin chain impair the synthesis of adult hemoglobin or lead to the 
production of abnormal adult hemoglobin. This leads to limited production of red 
cells or synthesis of abnormal red cells. For these reasons, patients require blood 
transfusion for survival. Before birth and during the first months of life, children 
express fetal hemoglobin, which comprises gamma- and alpha-chains. 
Generally, after birth the gene encoding the gamma-chain is silenced, while the 
beta-globin gene is activated, switching the production of hemoglobin from fetal 
to adult. In rare cases, individuals that do not silence the gamma-globin gene and 
also carry mutations in the beta-globin gene are spared from the disease 
associated with reduced or abnormal production of adult hemoglobin. Therefore, 
reactivation of fetal hemoglobin might be therapeutic in ameliorating diseases 
associated with mutations in the beta-globin gene. Activation and silencing of the 
gamma-globin gene depends on the proximity of a genomic region called locus 
control region (LCR), which maps ~40 to 60 kilobases upstream of the gamma- 
and beta-globin genes and is associated with many factors that activate 
transcription. This region is required to “loop” and bind the promoter of the gene 
that needs to be activated. When the gamma-globin gene is expressed, the LCR 
loops and binds on the gamma-globin promoter. After birth, the LCR moves away 
from the gamma-globin promoter and loops and binds the beta-globin promoter 
leading to silencing of the gamma gene and activation of the globin-gene. The 
transcription co-factor Ldb1 is involved in the LCR looping to the promoters of the 
gamma- and beta-globin genes. Ldb1 alone does not promote the binding of the 
LCR to the promoter, but requires additional factors. Artificial zinc-finger (ZF) 
proteins have the ability of binding specific sequences on the DNA.  Ldb1 has 
been fused to a specific ZF protein that binds the gamma-globin promoter. In 
transgenic mice, this protein promotes the looping and binding of the LCR to the 
promoter of the gamma globin gene, activating its expression (Deng, W., et al. 
Controlling long-range genomic interactions at a native locus by targeted 
tethering of a looping factor. Cell 149, 1233-1244 (2012)). 
An alternative way to approach therapy of hemoglobinopathies associated 
with mutation in the beta-globin gene is by inserting in the bone marrow cells 
(and in particular in the hematopoietic stem cells or HSCs) a functional beta-
globin gene. Therefore, gene transfer of the non-mutated form of the beta-globin 
gene by lentiviral vectors could potentially restore production of the human beta-
globin protein in patients and be utilized for gene therapy trials. Lentiviral vectors 
are well characterized for their ability to infect and insert the human beta-globin 
gene into HSCs.  In this regard, the present disclosure provides novel viral 
vectors that are designed for prophylaxis and/or therapy of hemoglobinopathies.  
The viral vectors include but are not necessarily limited to lentiviral vectors.  In 
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various embodiments an isolated mammalian hematopoietic progenitor cell or an 
isolated mammalian stem cell comprising a recombinant lentiviral vector is 
provided. 
Various embodiments of lentiviral vectors that are subjects of this 
disclosure are shown in Figure 11.  Features of these vectors include but are not 
necessarily limited to the capability to, when introduced to an appropriate cell: 1) 
reactivate expression of fetal hemoglobin, and/or 2) express a novel transgene 
adult hemoglobin and/or, concurrently, 3) inactivate the expression of mutant 
hemoglobin.  Certain features of the vectors are known in the art, and Figures 13 
and 14 provide representative sequences of them.  In particular, any suitable 
IRES sequence can be used, and those skilled in the art will recognize, given the 
benefit of this disclosure, which promoter sequences can be adapted for use in 
embodiments of the invention.  Likewise, the LCR sequence is known in the art, 
as are suitable polyadenylation signals that can function, for example, in 
erythrocytes.  The representative sequences of this disclosure, such as those 
shown in Figures 13 and 14, can be altered according to well-known parameters, 
so long as they impart to erythrocytes the ability to produced therapeutically 
effective amounts of elevated globin.  In certain cases polynucleotide sequences 
can be identical to those presented herein, or they can have least 80, 81, 82, 83, 
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity across a 
contiguous segment of the sequences. 
It is expected that lentiviral vectors of this disclosure will result in the 
expression of therapeutic levels of hemoglobins where previous vectors have 
failed to do so.  In embodiments, these vectors can be specifically adapted to 
optimize production of beta-globin plus gamma-globin mRNA, and protein levels 
in presence of different mutations associated with beta-thalassemia, sickle cell 
anemia and other hemoglobinopathies.  Certain aspects of this disclosure involve 
combinations of genomic elements, specific embodiments of which are depicted 
schematically in Figure 11.  The disclosure includes each and every 
polynucleotide sequence disclosed herein, the RNA equivalent of every DNA 
polynucleotide (i.e., where uracil replaces thymine) and every DNA equivalent of 
every RNA, and the complementary sequence and the reverse complement of 
every polynucleotide sequence.  The disclosure includes every amino acid 
sequence, and all polynucleotide sequences encoding the amino acid 
sequences.  Contiguous segments of polynucleotides and polypeptides 
sequences are also included.  In non-limiting examples, sequences of this 
disclosure can comprise or consist of any one or any combination of the 
contiguous segments of each vector construct disclosed herein, including but not 
limited to the segments and sequences depicted in Figures 11, 13, 14 and 15, 
the RNA equivalents thereof, and the DNA and RNA reverse complements 
thereof.  In aspects of the disclosure integration of a lentiviral vector of the 
disclosure results in an integrated functional globin gene, the expression of which 
produces a globin molecule that is effective to a participate in providing a 
therapeutic benefit to an individual with a globinopathy.  The gene may exhibit 
conditional expression, such as being expressed in erythrocytes, but not being 
expressed in for example, hematopoietic stem cells comprising an integrated 
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DNA segment derived from the lentiviral construct, wherein the stem cells 
differentiate into the erythrocytes that express the globin molecule.  The 
disclosure also includes cells, which comprise the recombinant polynucleotides.   
The present disclosure includes a demonstration of using the ALS10 lentiviral 
vector depicted in Figure 11 to elevate HbA production in cells from 
hemoglobinopathy patients.  In particular, the disclosure includes a 
demonstration that the ALS10 vector is superior to previously available 
approaches for improving HbA production in the most severe thalassemic 
specimens, i.e., those individuals with β0/0 phenotype.  In this regard, the 
disclosure provides a demonstration of using ALS10 to modify CD34+ cells from 
β0/0 phenotype patients such that HbA production is improved relative to a 
suitable control, and those skilled in the art will recognize suitable controls given 
the benefit of this disclosure.  In embodiments, the control can be a single value 
or a range of values. For example, a control can be a standardized curve or an 
area on a graph.  In one embodiment the control comprises the increase in HbA 
produced using a construct described in Breda, L., et al., Therapeutic 
hemoglobin levels after gene transfer in beta-thalassemia mice and in 
hematopoietic cells of beta-thalassemia and sickle cells disease patients. PLoS 
One, 2012. 7(3): p. e32345, which is known in the art as “AnkT9W.”   
In more detail, and without intending to be constrained by any particular theory, 
the approach of the current disclosure was taken in part in an effort to increase 
adult hemoglobin in thalassemic and SCD cells in a tissue specific manner, and 
proportionally to the number of viral molecules inserted. To attempt to reduce 
genome toxicity believed to be caused by random integration of viral vectors, we 
strived to maintain viral integration within an average of 2 copies/cell.  
It has been demonstrated in thalassemic specimens with moderate to medium 
range of HbA reduction (β+/+ and β+/0, respectively) 0.6 copies of AnkT9W were 
sufficient to generate HbA levels comparable to those detected in healthy or 
carrier cells, which is about 80-90% (Breda et al, Plos One, 2012).  However, in 
specimens with the most severe phenotype, β0/0, in which no adult HbA is 
observed, 0.6 copies of AnkT9W could not meet the level of adult hemoglobin 
observed in healthy or carrier cells, which was a therapeutic threshold that we 
strived to achieve in the presently provided approach.  In connection with this we 
modified AnkT9W to generate ALS10. In ALS10, the Woodchuck Post-
Regulatory Element (WPRE) was eliminated from the integrating sequence to 
increase the safety of the vector.  The WPRE was part of the integrated portion 
of AnkT9W since it was placed between the LCR and the 3' LTR.  The original 
purpose of the WPRE was to increase the titer of the lentivirus as it had been 
previously shown to have that effect, but we have now determined that it is 
dispensable in the current position. WPRE is a viral sequence and is not required 
for the expression of the beta-globin gene. It is considered safer to limit as much 
as possible the amount of viral sequences that are integrated in the genome of 
patient cells. For this reason, we moved this sequence in the vector to the non-
integrating region.  This preserves the WPRE’s ability to produce high titers of 
viral particles but excludes the WPRE from the genome of patient cells. In order 
to preserve the ability of WPRE to increase viral titers without having it in the 
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integrating sequence, we removed the WPRE from the integrating portion (before 
the 3’LTR) and added it back after the 3'LTR so that it is positioned outside the 
sequence that is integrated in the chromosome(s) of target cells.  We also added 
a strong bovine growth hormone polyA tail after the WPRE region (outlined in 
Figure 11). Our data indicate that the modifications do not decrease viral titer 
during production of compositions of this disclosure.  However, we also modified 
the segment of the construct that results in expression of HbA in erythrocytes 
that are derived from CD34+ cells into which the lentiviral vector is introduced.  In 
particular, the portion of the beta-globin gene intron 2 that is deleted in the 
AnkT9W construct is annotated in Figure 14.  As can be seen from that 
annotation, the beta-globin gene intron 2 encompasses nucleotides 4772 – 5621, 
inclusive, and is thus 851 nucleotides in length.  However, the intron 2 in 
AnkT9W comprises a deletion of the 375 nucleotides spanning nucleotides 5,164 
through 5,537, inclusive (as designated in Figure 14).  As a consequence of that 
deletion, the AnkT9W beta-globin gene intron 2 is 476 nucleotides in length.  In 
contrast, and while not intending to be bound by any particular theory, it is 
considered that including a longer segment of intron 2 in the context of the 
ALS10 construct is at least partially responsible for the unexpected and 
statistically significant increase in HbA in the β0/0 patient cells.  In this regard, 
when compared to AnkT9W, ALS10 showed significant improvement and in 
particular leads to much higher level of HbA in the most severe thalassemic 
patient specimens, namely, the β0/0 phenotype.  It is therefore reasonable 
expect that the present approach will benefit patients with hemoglobinopathies 
that are not necessarily due to a β0/0 phenotype, such as SCD.  A summary of 
the results demonstrating this advantage of ALS10 is presented in Figure 12.  
The disclosure thus includes lentiviral vectors and cells comprising them, and the 
integrated construct, wherein the beta-globin gene comprises an intron 2 of more 
than 476 nucleotides in length, and up to 851 nucleotides in length.  The intron is 
accordingly between 477-875 nucleotides, inclusive, and including all integers 
and ranges of integers there between.  The intron 2 can be thus comprise or 
consist of 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 
491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 
507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 
523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 
539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 
555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 
571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 
587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 
603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 
619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 
635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 
651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 
667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 
683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 
699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 
715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 
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731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 
747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 
763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 
779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 
795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 
811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 
827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 
843, 844, 845, 846, 847, 848, 849, 850, 851 nucleotides.  The polynucleotide 
sequence of the human beta globin gene is depicted in Figure 13.  It includes the 
3’ enhancer element, the 3’ untranslated region (UTR), the polyA signal, exon 3, 
intron 2, exon 2, intron 1, exon 1, the 5’ UTR, and the beta globin promoter 
segment.  It is shown in the 3’-5’ orientation because, as is well known in the art, 
it is anti-parallel to the depicted remainder of the construct and is expressed only 
after integration and in the context of a double stranded DNA region wherein one 
strand of the DNA comprises the beta globin gene sequence presented in Figure 
14. 
 In ALS10 the sequence of the beta-globin gene is also modified to 
increase its ability to prevent the sickling of the sickle-beta-globin chains (referred 
to as “B-globinM” in Figure 11). This mutant beta-globin is known as the βT87Q 
form, due to its amino acid substitution at the 87th position.  βT87Q has been 
used to improve hematological parameters of the SAD and BERK mouse models 
of SCA (Pawliuk, R., et al. Correction of sickle cell disease in transgenic mouse 
models by gene therapy. Science 294, 2368-2371. (2001)).  This form was also 
used in the first successful clinical trial to correct a patient with β0/βE 
thalassemia (Cavazzana-Calvo, M., et al. Transfusion independence and 
HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 
318-322 (2010)).   
The ankyrin insulator that is well known in the art and was present in 
AnkT9W is also present in ALS10.  ALS10 has the ankyrin insulator in the 3’LTR, 
while the vector AnkT9W has the ankyrin insulator between the promoter and the 
LCR.   
In one aspect of this disclosure, an intron of the beta-globin gene, or other 
locations such as the 3’UTR, can be modified to include a polynucleotide that 
targets and decreases the synthesis of the transferrin receptor 1 (TR1). The 
rational of this approach is based on our observations that decreased erythroid 
iron intake can be beneficial in beta-thalassemia and, potentially other 
hemoglobinopathies, because this decreases formation of heme molecules. 
Heme is normally included in hemoglobin molecules but in many 
hemoglobinopathies, due to the reduction in synthesis of beta-globin chains, 
there is an excess of heme not bound to hemoglobin, and these molecules are 
toxic to red cells. An excess of heme is responsible for apoptosis of erythroblasts 
and for altering the intracellular content, production of reactive oxygen species 
(ROS), and for reducing membrane stability and plasticity of erythrocytes, leading 
to their reduced lifespan, hemolysis and/or sickling. A combination vector that 
expressed gamma-globin and concurrently knocked-down sickle beta-globin via 
small hairpin RNA has been described (Samakoglu, S., et al. A genetic strategy 
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to treat sickle cell anemia by coregulating globin transgene expression and RNA 
interference. Nature biotechnology 24, 89-94 (2006)) and this approach can be 
incorporated in embodiments of the present disclosure (i.e., Figure 11, in ALS-
10T, signified by “I1S”).  With respect to polynucleotides that target TR1 and that 
can be included in vectors of this disclosure, shRNA is one non-limiting example 
of an RNAi-mediated approach.  But RNAi-based inhibition can be achieved 
using any suitable RNA polynucleotide that is targeted to TR1 mRNA.  With 
respect to shRNAs, they are known in the art to adopt a typical hairpin secondary 
structure that contains a paired sense and antisense portion, and a short loop 
sequence between the paired sense and antisense portions.  shRNA is delivered 
to the cytoplasm where it is processed by DICER into siRNAs.  siRNA is 
recognized by RNA-induced silencing complex (RISC), and once incorporated 
into RISC, siRNAs facilitate cleavage and degradation of targeted mRNA.  In 
embodiments, an shRNA polynucleotide segment or DNA segment encoding it 
included for use in suppressing TR1 expression can comprise or consist of 
between 45-100 nucleotides, inclusive, and including all integers between 45 and 
100.  The portion of the shRNA that has reverse complementarity to the TR1 
mRNA mRNA can be from 21-29 nucleotides, inclusive, and including all integers 
between 21 and 29.  In another approach, a ribozyme that can specifically cleave 
TR1 mRNA can be included.  In another embodim
targeted to the TR1 mRNA can be used.   
The present disclosure provides an illustration that vector encoding a 
fusion of an Ldb1 transcription factor and a zinc finger (ZF) domain (ZF-Ldb1) is 
useful for approaching certain hemoglobinopathies.  A ZF-Lbd1 gene can be 
incorporated into vectors of this disclosure in several configurations.  In one non-
limiting approach using ALS-10 in Figure 11 as a representative example, the 
ZF-Ldb1 gene can be positioned such that the vector comprises consecutively 
(with the same stranded-ness as the beta-globin coding sequence) the 5’LTR, a 
polyadenylation signal, the ZF-Ldb1 region and a either a promoter that can drive 
expression of a separate mRNA encoding the ZF-Ldb1 protein, or an IRES so 
that the mRNA encoding the ZF-Ldb1 protein can be made as a distinct protein, 
but from the same mRNA that encodes the beta-globin protein.  The rational for 
including ZF-Ldb1 into ALS is twofold: 1) the ZF-Ldb1 will move the LCR from the 
promoter of the mutant beta-globin gene to that of the gamma-globin gene. In 
this way the production of mutant RNA will be reduced or shut down, while 
expression of the functional gamma-globin gene will be activated: 2) The 
expression of transgenic beta-globin gene (considered to be a potentially curative 
gene carried by the lentiviral vector) will not be affected in the presence of ZF-
Ldb1. Without intending to be constrained by theory this is expected to lead to an 
additive or synergistic effect by the production of both hemoglobins: fetal 
hemoglobin (HbF, α2γ2, from the endogenous locus), and adult hemoglobin 
(HbA or α2β2, from the therapeutic vector). As hemoglobinopathies in humans 
are characterized by more than 300 mutations, it is reasonable to predict that the 
many or all hemoglobinopathies could be improved by a vector of this disclosure.  
In this regard, we demonstrated that a lentiviral vector encoding the ZF-Ldb1 
cassette (pCL-ZF-Ldb1) increases synthesis of fetal hemoglobin (HbF, α2γ2) in 
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CD34-derived erythroid cells from normal individuals and SCA patients. As HbF 
increased, the synthesis of adult hemoglobin (HbA) or sickle hemoglobin (HbS or 
α2βs2) diminished, respectively in cells derived from normal individuals or SCA 
patients.  We also investigated the number of vectors integrated per cell, on 
average. This number is indicated as number of integration per cell or vector 
copy number (VCN). We observed that the increase in VCN was associated with 
an increase of HbF both in normal and SCA cells. The number of HbF positive 
cells measured by flow cytometry also increased proportionally to the VCN. β, γ- 
and α-globin mRNA levels measured by quantitative PCR also showed that the 
relative ratio γ/α increased while the β/α or βS/α were reduced in the samples 
treated with the ZF-Ldb1 vector.  Taken together these data suggest that the ZF-
Ldb1 can redirect the LCR enhancing effect from the β-globin promoter to the γ-
globin promoter.  In SCA this effect is particularly beneficial  given the toxicity 
caused by the accumulation of HbS. Examples 1-6 further confirm potential 
usefulness of including ZF-Ldb1 in ALS10.  In particular, these Examples 
demonstrate infection of hematopoietic stem cells isolated from blood of SCD 
patients with a lentivirus expressing the ZF-Ldb1 transgene and differentiation of 
them into mature erythroid cells in vitro. HbF synthesis induced by ZF-Ldb1 was 
compared to that obtained in specimens treated with hydroxyurea and various 
additional HbF inducers.  ZF-Ldb1 increased HbF synthesis and simultaneously 
reduced sickle Hb (HbS), establishing a balanced synthesis between α- and 
functional β-like globins. The induction of HbF in cells treated with ZF-Ldb1 was 
roughly three times higher (+34%), than that observed using decitabine and 
pomalidomide; tranylcypromine had an intermediate effect, while butyrate and 
hydroxyurea showed marginal HbF induction. Notably, erythroid cell 
differentiation and viability remained unaltered in ZF-Ldb1 expressing cells.  
Thus, lentiviral-mediated ZF-Ldb1 gene transfer appears superior to existing drug 
regimens for affecting SCD erythroid cells and it is reasonable to expect that 
combining ZF- to an ALS10 vector will provide an effective approach to 
prophylaxis and/or therapy of a variety of hemoglobinopathies.   The Examples 
provide also provide a demonstration of the effectiveness of ALS10 in β0/0 
patient cells. 
Compositions comprising recombinant lentiviral vectors are provided.  In certain 
approaches pharmaceutical compositions are provided and can be prepared by 
mixing, for example, virions comprising a lentiviral vector of this disclosure and 
any suitable pharmaceutically acceptable carriers, excipients and/or stabilizers.  
Some examples of compositions suitable for mixing with IL-8 can be found in: 
Remington: The Science and Practice of Pharmacy (2005) 21st Edition, 
Philadelphia, PA. Lippincott Williams & Wilkins.  In certain approaches.   
The disclosure includes methods of making a virion preparations for use in 
prophylaxis and/or therapy of hemoglobinopathies.  In one embodiment this 
method comprises introducing a plasmid encoding a lentiviral vector of this 
disclosure into packaging cells.  The packaging cells comprise a DNA packaging 
plasmid, which encodes at least one virion protein, and a DNA envelope plasmid, 
which encodes a suitable viral envelope protein.  The packaging and envelope 
plasmids express the respective proteins, which facilitate formation of virions 
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which comprise a recombinant RNA lentiviral vector of this disclosure.  Suitable 
packaging systems that can be adapted to produce virions of this disclosure are 
commercially available, such as from Addgene (Australia).  
 
The following Examples are intended to illustrate various aspects of the present 
disclosure but are not meant to be limiting in any way. 
 
Example 1 
This Example demonstrates that lentivirally expressed ZF-Ldb1 raises HbF levels 
in CD34+-derived sickle erythroblasts. To obtain the data presented here, we 
used the lentiviral vector pCL-ZF-Ldb1, (Fig. 11, top vector map), which carries a 
zinc-finger protein that specifically binds the γ-globin promoters, fused to the self-
association (SA) domain of Ldb1, as well as a green fluorescent protein under 
the control of the erythroid specific ankyrin promoter. The effects of ZF-Ldb1 
expression on chromatin contacts within the β-globin locus have been shown 
using 3C experiments in healthy adult erythroblasts. ZF-Ldb1 expression 
promotes the juxtaposition of the γ-globin promoters with the LCR leading to 
transcription [Deng, W., et al., Reactivation of developmentally silenced globin 
genes by forced chromatin looping. Cell, 2014. 158(4): p. 849-60]. This is 
accompanied by a concomitant reduction in the expression of adult globin genes, 
compatible with a mechanism in which the fetal and adult promoters compete for 
LCR enhancer activity. This example describes an attempt to improve the 
amount of functional hemoglobin in CD34+ cells isolated from sickle cell patients. 
Sickle CD34+ cells produce predominantly HbS (α2βs2) once differentiated into 
erythroblasts in vitro. Other hemoglobins, as HbF (α2γ2) and HbA2 (α2δ2) are 
also produced to a lower degree (Fig. 1A, left). Following infection with pCL-ZF-
Ldb1 vector, sickle cells dramatically increased HbF synthesis in a manner 
proportional to the copy number of viral integrants. In a representative 
experiment the same SCD derived erythroid cells (shown in Fig. 1A, left) 
transduced with 0.26 or 0.67 viral molecules on average per cell (VCN or vector 
copy number) produce 22% or 44% (Fig. 1A, middle and right, respectively) more 
HbF than the control sample. Concomitantly, with progressively higher viral 
integration the number of HbF (Fig. 1B) and GFP (Fig. 1C) expressing 
erythroblasts increased, as determined by flow cytometry measurements. The 
gain in the fraction of GFP+ cells is somewhat lower, likely the result of reduced 
translation efficiency that is often observed downstream of the internal ribosomal 
entry site (IRES) between the ZF-Ldb1 cassette and the GFP gene. 
 
Example 2 
This Example demonstrates that transgenic ZF-Ldb1 supports high levels of fetal 
globin induction and concurrently reduces sickle globin levels in SCD 
erythroblasts.  In particular, we analyzed the mRNA and protein content of 
erythroblasts derived from 10 SCD subjects. CD34+ cells isolated from peripheral 
blood mononuclear cells (PBMCs) were frozen and used for independent 
replicate experiments. Infection with pCL-ZF-Ldb1 was performed on pro-
erythroblast within the first 10 days of the expansion phase. At this time cells still 
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express high levels of CD1117 and CD44 markers and do not express 
glycophorin A (data not shown) (Breda, L., et al., Therapeutic hemoglobin levels 
after gene transfer in beta-thalassemia mice and in hematopoietic cells of beta-
thalassemia and sickle cells disease patients. PLoS One, 2012. 7(3): p. e32345).  
To assess the ability of ZF-Ldb1 to reactivate HbF we measured the amount of γ-
globin mRNA expressed in cells untreated or after transduction. These values 
were normalized to GAPDH and to α-globin gene expression whose expression 
is directly proportional to the erythroid differentiation stage in the cells. Cells with 
1.1 copies of pCL-ZF-Ldb1 produced on average a 3-fold increase of the γ/α 
globin ratio (from 0.2 ± 0.11 to 0.6 ± 0.33), compared to untreated cells and, 
simultaneously, a reduction of the β/α ratio (from 0.38 ± 0.08 to 0.29 ± 0.16) (Fig. 
2A, left and center), confirming the ability of the ZF-Ldb1 construct to partially 
redirect the LCR from the β- to the γ-globin promoter. These changes were 
observed only in cells expressing transgenic Ldb1, whose expression was 
proportional to the level of ZF-Ldb1 integration (Fig. 2A, right).  
On average, cells treated with pCL-ZF-Ldb1 produced nearly 40% more HbF 
(63.10% ± 14.01) compared to untreated cells (27.27% ±16.29) (Fig. 2B, left) and 
lowered production of HbS (-35.65%) and HbA2 (-5.18%) (Fig. 2B, center and 
right). Reduction of HbA2 is likely the result of reduced contact frequencies 
-globin and the LCR in the presence of ZF-Ldb1. A summary of net 
HbA increase and HbS and HbA2 decrease is provided in Fig. 3C.  
 
Example 3 
To establish the effect of ZF-Ldb1 treatment on the total amount of cellular Hb we 
measured absolute Hb content per differentiated cell. Importantly, in spite of 
significant shifts in the ration of fetal to adult globin, total Hb synthesis changes 
(HbF+HbS+HbA2) remained essentially unaltered (Fig. 3A, right). To corroborate 
this evidence is the fact that βS chains are diminished while both γA+γG chains 
are increased in specimens treated with ZF-Ldb1, analyzed by reversed-phase 
liquid chromatography (Fig. 3B and S1) which allows for the quantification of 
single globin chains rather than to tetrameric hemoglobin abundance. The 
reduced amount of HbS was confirmed by flow cytometry (Fig. 4). ZF-Ldb1-
expressing SCD erythroblasts, which can be tracked by GFP expression (Fig. 
4A), have a greater fraction of HbF positive cells (Fig. 4B), and within the HbF 
positive population, a lower fraction of HbS compared to untransduced SCD 
erythroblasts (Fig 4C). Untreated baseline HbF positive erythroblasts (Fig. 4B, 
center) were less frequent and contained less than half the HbF/erythroid cell 
when compared to the ZF-Ldb1 expressing cells (Fig. 4D). 
 
Example 4 
This Example demonstrates that γ-globin gene repressors SOX6 and KLF1 are 
down regulated in sickle erythroblasts.  In particular, BCL11A, SOX6, C-MYb and 
KLF1 have emerged as salient repressors of γ-globin during erythroid 
differentiation. We investigated the impact of pCL-ZF-Ldb1 on transcription of 
these repressors in both wild type and sickle cell disease derived erythroid cells. 
RT-qPCR analyses indicates that differentiated erythroblasts obtained from SCD 
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patients present a different pattern of expression for certain negative regulators 
of γ-globin gene expression, compared to erythroblasts obtained from healthy 
individuals. BCL11A and C-MYB messenger RNAs present comparable level of 
expression (Fig. 5A), whereas both KLF1 and SOX6 show significant down 
regulation in SCD specimens (0.17 ± 0.05 and 4.49 ± 0.76, respectively) 
compared to healthy ones (0.55 ± 0.43 and 8.29 ± 3.14, respectively) (Fig. 5B). 
All samples analyzed present similar expression of KEL, an internal control 
mRNA that increases with level of differentiation. These trends are independent 
from the level of transgene expression (Fig. 5 and 5C, right). These data could 
indicate a more permissive chromatin state of the γ-globin gene in SCD cells in 
culture, as suggested by a trend of higher content of HbF at steady state in these 
cells compared to healthy ones (Fig. 7).  
 
Example 5 
This Example demonstrates that HbF induction in SCD erythroblasts ZF-Ldb1-
mediated is greater than induction mediated by pharmacological inducers.  A 
scheme of the experimental procedures is illustrated in Table 1. Briefly, erythroid 
progenitor SCD cells were infected with pCL-ZF-Ldb1 within days 9-11 in 
expansion phase, or treated at days 1 and 3 of differentiation phase with 
pharmacological inducers 5-aza-2’-deoxy-cytidine (0.5μM), tranyl-cypromine 
(1.5μM), hydroxyurea (150 μM), pomalidomide (30μM), and butyrate (100 μM), 
These concentrations were determined through evaluation of efficacy (net 
increase of HbF) versus toxicity (cell death); the original scaling dosage was 
extrapolated from the recent literature (Fig. 9) [Watanapokasin, Y., et al., In vivo 
and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-
thalassemia/hemoglobin E patients. Exp Hematol, 2005. 33(12): p. 1486-92; 
Moutouh-de Parseval, L.A., et al., Pomalidomide and lenalidomide regulate 
erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin 
Invest, 2008. 118(1): p. 248-58; Shi, L., et al., Lysine-specific demethylase 1 is a 
therapeutic target for fetal hemoglobin induction. Nat Med, 2013. 19(3): p. 291-4]. 
Studies were performed on day 8 of differentiation phase, at the 
orthochromatophilic stage when high amounts of hemoglobin were accumulated. 
As measured by HPLC, pCL-ZF-Ldb1 had the most robust increase of HbF and 
decrease in HbS. Specifically, on average the net HbF increase in SCD 
erythroblast treated with the lentivirus was 34.2% ± 12.53, versus 15.19% ± 
12.77 with 5-aza-cytidine (p<0.01), 8.08% ± 6.28 with tranyl-cypromine 
(p<0.001), 2.39% ± 2.13 with hydroxyurea (p<0.001), 11.84% ± 9.02 with 
pomalidomide (p<0.01), and 4.84% ± 5.03 with butyrate (p<0.001). ZF-Ldb1 
expressing cells presented HbF significantly higher than untreated cells 
(p<0.001) (Fig. 6A, top). Conversely, on average the net HbS decrease in SCD 
erythroblast treated with the lentivirus was -31.36% ± 11.61, versus -17.30% ± 
15.04 with 5-aza-cytidine, -6.93% ± 6.64 with tranyl-cypromine, -3.48% ± 4.68 
with hydroxyurea, 11.61-% ± 9.27 with pomalidomide, and -4.90% ± 7.94 with 
butyrate (Fig. 6A, bottom).  
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Along with recovery of greater levels of functional Hb, cells expressing ZF-Ldb1 
did not show significant changes in viability compared to untreated samples, 
whereas cells treated with pomalidomide, butyrate and hydroxyurea showed 
reduced viability (Fig. 6B). These differences were confirmed in a subset of 
samples treated with pharmacological inducers at earlier time points (Table 2) to 
exclude biases due to a delay to drug response (Fig. 10). Taken together, pCL-
ZF-Ldb1 was superior to all tested compounds in augmenting HbF and F-Cell 
levels and importantly was associated with minimal toxicity. 
 
 
It will be apparent from the foregoing that a lentiviral vector carrying the SA Ldb1 
domain linked to a ZF protein, which selectively binds the γ-globin promoters, 
significantly increased HbF synthesis and exceeds previously described 
pharmacological inducers.  It is therefore reasonable that adding an SA Ldb1 
domain linked to a ZF protein to an ALS10 vector of this disclosure will likely 
enhance beneficial properties of the combined vectors.   
 
Example 6 
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This Example provides a description of the materials and methods used to obtain 
the results described in Examples 1-5. 
Human and Animal Ethics 
Peripheral blood samples from SCD patients were obtained during automated 
red cell exchange as part of their routine clinical care at Montefiore Medical 
Center. Since the samples were unlinked and de-identified medical waste, the 
Montefiore Medical Center Institutional Review Board deemed them to be IRB 
exempt.  
Construct 
The ZFs targeting HS2 of the human γ-globin promoters are known in the art. 
The SA domain containing amino acids 1–200 of Ldb1 was inserted C-terminal to 
the ZF. The SA domain was attached in C-terminal to GG1 tagged with HA. 
Vector production and titration 
Viral stocks were generated by co-transfection of the gene transfer plasmid (pCL-
ZF-Ldb1) together with the envelope plasmid (VSV-G), the packaging plasmid 
(pMDLg/p RRE), and the pRSV-REV plasmid into 293T cells. An aliquot (5×106) 
of 293T cells was seeded into cell culture dishes (10 cm) 24 hours prior to 
transfection in Iscove's modification of Eagle's medium (DMEM, Cellgro, 
Manassas, VA) with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml 
streptomycin, at 37°C under 5% CO2. The culture medium was changed 2 hours 
prior to transfection. The precipitate was formed by adding the plasmids to 450 
uL of 0.1× TE (0.1× TE is 10 mM Tris plus 1 mM EDTA) and 50 µL of 2 M CaCl2, 
then adding 500 µL of 2× HEPES-buffered saline (281 mM NaCl, 100 mM 
HEPES, 1.5 mM Na2HPO4) drop wise after which the precipitate was vortexed 
and immediately added to the cultures. The medium (10 ml) was replaced after 
16 hours. Viral supernatants were collected at 24 and 48 hours, cleared by low 
speed centrifugation, and filtered through cellulose acetate (0.2 µm). Following 
ultracentrifugation, serial dilutions of concentrated virus (5; 0.5 and 0.05 µL, 
respectively) were used to infect 1×105 NIH 3T3 cells (ATCC, Manassas, VA) in 
1 mL of transfection buffer complemented with polybrene (Millipore, Billerica, MA) 
at a final concentration of 8 µg/mL. Genomic DNA was extracted after 3 days 
(Qiagen kit, Valencia, CA). The multiplicity of infection (MOI) was calculated 
using the following formula: number of cells (1×105) X dilution factor (1 mL/µL 
viral preparation) X VCN (measured via real-time PCR, using oligos for WPRE 
element and ID gene, see PCR and Real Time PCR). 
Real Time (RT)-PCR 
Retrotranscription of total mRNA was done using the SuperScript™ II First 
Strand Kit (Invitrogen, Carlsbad, CA). Q-PCR reactions were performed using the 
ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, 
CA), with either TaqMan (TaqMan PCR 2× Master mix; Applied Biosystems) or 
SYBR Green (iTaqTM SYBR® Green Supermix, Bio-Rad Laboratories, Hercules, 
CA) chemistry. Quantitative real-time PCR assays of globin and GAPDH 
transcripts were carried out using gene-specific double fluorescently labeled 
probes. The following primer and probe sequences were used (forward, reverse 
and probe, when used, of each gene, respectively): β: Fw: 5′-
CAAGAAAGTGCTCGGTGCCT-3′ (SEQ ID NO:6); Rev: 5′- 
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GCAAAGGTGCCCTTGAGGT-3′ (SEQ ID NO:7); 5′-FAM-
TAGTGATGGCCTGGCTCACCTGGAC-TAMRA-3′ (SEQ ID NO:8); α: Fw: 5′-
TCCCCACCACCAAGACCTAC-3′ (SEQ ID NO:9); Rev: 5′-
CCTTAACCTGGGCAGAGCC-3′ (SEQ ID NO:10); 5′-FAM-
TCCCGCACTTCGACCTGAGCCA-TAMRA- -
TGGCAAGAAGGTGCTGACTTC-3′ (SEQ ID NO:12); Rev: 5′-
TCACTCAGCTGGGCAAAGG (SEQ ID NO:13); 5′-FAM-TGG 
GAGATGCCATAAAGCACCTGG-TAMRA-3 (SEQ ID NO:14)′; BCL11A: Fw: 5′-
TGATGTGTGTCCATTGGTGTGAGC-3′ (SEQ ID NO:15); Rev: 5′-
TGCGAACTTGAACGTCAGGAGTCT, SOX-6 (SEQ ID NO:16): Fw: 5′-
AGCTGCTTTCGGCTTTCTCCCTTA-3′ (SEQ ID NO:17); Rev: 5′-
CCTTTGCATTTGCAGCAGTTCAGC-3′ (SEQ ID NO:18); C-MYB: Fw: 5′-
TCAACCGATCATCCCTCACACTCT-3 ′ (SEQ ID NO:19)′; Rev: 5′-
AATCAGCAGCGCTTCCATTCAAGG-3’ ′ (SEQ ID NO:20), KLF-1: Fw: 5′-
GCTGCCTCCACCCAAGTG-3′ (SEQ ID NO:21); Rev: 5′-
ACCAACTCTGGGCAGTCACAT-3’ (SEQ ID NO:22), Kell: Fw: 5′-
AGCAACCACCCATGCCTGCC-3′ (SEQ ID NO:23); Rev: 5′-
CTCGGGCCAAAGGCCTCACG-3′ SEQ ID NO:24). For real-time PCR of the 
reference genes, we used as an endogenous control the human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) kit, in which the probe is fluorescently 
labeled with VIC (Applied Biosystems). The number of integrations (VCN) was 
quantified by Q-PCR using oligos (Fw: 5′-CGGCTGTTGGGCACTGA-3′ SEQ ID 
NO:25); Rev: 5′-GGAAGGTCCGCTGGATTGA-3′ SEQ ID NO:26)) and a probe 
(5′-FAM-ATGGCTGCTCGCCTGTGTTGCC-TAMRA-3′ SEQ ID NO:27) for a 
specific sequence present in the vector (WPRE) and compared it to an 
endogenous control present in two copies within the genome (ID-1 Fw: 5′-
AAGGTGAGCAAGGTGGAGATTC-3 SEQ ID NO:28)′; Rev: 5′-
TTCCGAGTTCAGCTCCAACTG-3′ SEQ ID NO:29). 
Two-phase liquid cultures, benzidine staining and transduction 
CD34+ cells selection from blood samples was performed by immunomagnetic 
separation, using the CD34 microbeads kit (Miltenyi Biotec Inc., Auburn, CA). 
These cells were then expanded following a modified version of the protocol 
described by Leberbauer and colleagues. Cells were seeded in 5 mL of serum-
free StemSpan with 50 µL of StemSpan CC-100 cytokine cocktail (both from 
Stemcell Technologies, Vancouver, BA, Canada), 2 U/mL Erytrhopoietin (Amgen, 
Thousand Oaks, CA), 10−6 M dexamethasone (Sigma) and 1% penicillin 
streptomycin. CD34+ cultures were kept undifferentiated by refreshing the 
medium twice a week and density gradient centrifugation was used to remove 
both dead and spontaneously differentiating cells. At this stage cells were either 
frozen (with 50% characterized Hyclone FBS, 10%DMSO, Sigma, and 40% 
Iscove's Modified DMEM, Cellgro), or used for experiments. After 10 days in 
phase I, cells were transferred into phase II media containing α-modified 
essential medium supplemented with 30% fetal calf serum and 10−5 M β-
mercaptoethanol. Erythropoietin was added (5 U/mL) to stimulate erythroid 
differentiation. Cells were infected with serial dilutions of the virus. Cells were 
collected on day 7-10 of phase II for all analyses. The level of differentiation was 
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assessed by benzidine staining. At this stage, cells were analyzed by flow 
cytometry for GFP, HbF and HbB expression. 
Treatment with HbF inducers 
We treated peripheral blood derived CD34+ cells (see procedure) with HbF 
inducer drugs: Hydroxyurea (HU), 5-azacytidine, pomalidomide, sodium butyrate, 
Tranyl-cypromine (TCP). Tranyl-cypromine (TCP), 5-aza-2’-deoxy-cytidine, 
pomalidomide and sodium butyrate. We first titrated the drugs to find the most 
efficient and less toxic concentration according to published data. Hydroxyurea 
(HU; Sigma-Aldrich), dissolved in water, was added to the culture medium at final 
concentrations of 150 μM. Tranylcypromine (Sigma-Aldrich) was dissolved in 
water and added to the culture medium at final concentrations 1.5 μM. 5-
azacytidine (DAC; Sigma-Aldrich) was dissolved in water and added to the 
culture medium at final concentrations of 0.5 μM. Pomalidomide (Sigma-Aldrich) 
was dissolved in DMSO and was added to the culture medium at final 
concentrations of 30 μM. Sodium butyrate (Sigma-Aldrich) was dissolved in water 
and added to the culture medium at final concentration of 100 μM. The treatment 
timeline is shown in Table I. 
Tetrameric and single chain analysis by high performance liquid chromatography 
(HPLC) 
Red cell pellets were lysed with HPLC-grade water, and the resulting membrane-
free hemolysates loaded into a System Gold 126 Solvent Module instrument 
(Beckman Coulter, Fullerton, CA). Hemoglobins were separated on a weak 
cation-exchange PolyCAT A column (PolyLC, Inc, Columbia, MD), and detected 
at a wavelength of 415 nm. The Hbs were bound to the column with mobile 
phase A (20 mmol/L Bis-Tris, 2 mmol/L KCN, pH 6.96) and eluted with mobile 
phase B (20 mmoI/L Bis-Tris, 2 mmol/L KCN, 200mmol/L NaCl, pH 6.55). Single 
chain quantification was assessed via reversed-phase HPLC. Hb samples in this 
case were injected on a Hitachi D-7000 HSM Series apparatus (Hitachi 
Instruments, San Jose, CA) using a Zorbax 5 µm 300SB-C8 300 Å, LC 150 x 2.1 
mm column (Agilent Technologies, Santa Clara, CA) and a gradient from 20% to 
60% acetonitrile in 0.1% trifluoroacetic acid in 25 minutes, with UV detection at 
215 nm. Serial dilutions of a solution with known concentrations of HbA and HbF 
(Analytical Control System, Inc, Fishers, IN) were used to generate a calibration 
curve, where the peak areas were plotted against the concentration values. 
Types and relative quantity of Hbs in samples were assessed by comparison to 
standard hemoglobin controls. 
 
Example 7 
This Example demonstrates that introducing the lentiviral vector ALS10 into 
CD34+ cells from β0/0 phenotype samples, and thus the most severe 
thalassemic specimens, results in statistically significantly elevated levels of HbA 
produced by erythrocytes derived from the modified CD34+ cells.  The elevation 
in HbA is relative to a previously describe construct, which is used in this 
Example as a comparison control (AnkT9W, from Breda et al, Plos One, 2012), 
which did not include a complete intron 2.  Thus, when compared to the 
previously described construct, ALS10 showed significant and unexpected 
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improvement, as demonstrated by the results depicted in Figure 12.  To obtain 
the results presented in Figure 12, the following materials and methods were 
used. 
Vector production and titration 
Viral stocks were generated by co-transfection of the gene transfer plasmid 
(GG1-SA) together with the envelope plasmid (VSV-G), the packaging plasmid 
(pMDLg/p RRE), and the pRSV-REV vector into 293T cells. An aliquot (5×106) of 
293T cells was seeded into cell culture dishes (10 cm) 24 hours prior to 
transfection in Iscove's modification of Eagle's medium (DMEM, Cellgro, 
Manassas, VA) with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml 
streptomycin, at 37°C under 5% CO2. The culture medium was changed 2 hours 
prior to transfection. The precipitate was formed by adding the plasmids to 450 
uL of 0.1× TE (0.1× TE is 10 mM Tris plus 1 mM EDTA) and 50 µL of 2 M CaCl2, 
then adding 500 µL of 2× HEPES-buffered saline (281 mM NaCl, 100 mM 
HEPES, 1.5 mM Na2HPO4) dropwise after which the precipitate was vortexed 
and immediately added to the cultures. The medium (10 ml) was replaced after 
16 hours. Viral supernatants were collected at 24 and 48 hours, cleared by low 
speed centrifugation, and filtered through cellulose acetate (0.2 µm). Following 
concentration by ultracentrifugation, serial dilutions of concentrated virus (5; 0.5 
and 0.05 µL, respectively) were used to infect 1×105 NIH 3T3 cells (ATCC, 
Manassas, VA) in 1 mL of transfection buffer complemented with polybrene 
(Millipore, Billerica, MA) at a final concentration of 8 µg/mL. Genomic DNA was 
extracted after 3 days (Qiagen kit, Valencia, CA). The multiplicity of infection 
(MOI) was calculated using the following formula: number of cells (1×105) X 
dilution factor (1 mL/µL viral preparation) X VCN (measured via real-time PCR, 
using oligos for Psi element and ID gene, by Real Time PCR). 
Two-phase liquid cultures, benzidine staining and transduction 
Consented patients with β0/0  and healthy individuals donated between 20 and 
30 mL of peripheral blood; alternatively 30 to 60 mL of peripheral blood from β0/0  
patients were obtained from the discarded blood from the red cell exchange 
therapeutic procedure. We selected CD34+ cells by immunomagnetic separation, 
using the CD34 microbeads kit (Miltenyi Biotec Inc., Auburn, CA) and then 
expanded these cells following a modified version of the protocol described by 
Leberbauer and colleagues. Cells were seeded in 5 mL of serum-free StemSpan 
with 50 µL of StemSpan CC-100 cytokine cocktail (both from Stemcell 
Technologies, Vancouver, BA, Canada), 2 U/mL Erytrhopoietin (Amgen, 
Thousand Oaks, CA), 10−6 M dexamethasone (Sigma) and 1% penicillin 
streptomycin. CD34+ cultures were kept undifferentiated by refreshing the 
medium twice a week and density gradient centrifugation was used to remove 
both dead and spontaneously differentiating cells. At this stage cells were either 
frozen (with 50% characterized Hyclone FBS, 10%DMSO, Sigma, and 40% 
Iscove's Modified DMEM, Cellgro), or used for experiments. After 10 days in 
phase I, cells were transferred into phase II media containing α-modified 
essential medium supplemented with 30% fetal calf serum and 10−5 M β-
mercaptoethanol. Erythropoietin was added (5 U/mL) to stimulate erythroid 
differentiation. Cells were infected with serial dilutions of the virus. Cells were 
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collected on day 7-10 of phase II for all analyses. The level of differentiation was 
assessed by benzidine staining. 
High performance liquid chromatography (HPLC) 
Cell pellets were lysed with HPLC-grade water and loaded into a System Gold 
126 Solvent Module instrument (Beckman Coulter, Fullerton, CA). Hemoglobins 
were separated on a PolyCAT A column (PolyLC, Inc, Columbia, MD), which is 
packed with silica-based material with a bonded coating of polyaspartic acid, and 
detected at a wavelength of 415 nm. The Hbs were bound to the column with 
mobile phase A (20 mmol/L Bis-Tris, 2 mmol/L KCN, pH 6.96) and eluted with 
mobile phase B (20 mmoI/L Bis-Tris, 2 mmol/L KCN, 200mmol/L NaCl, pH 6.55). 
Serial dilutions of a solution with known concentrations of HbA and HbF 
(Analytical Control System, Inc, Fishers, IN) were used to generate a calibration 
curve, where the absorbance detected at 415 nm was plotted against the 
concentration values. Types and quantity of hemoglobins in samples were 
assessed by comparison to standard hemoglobin controls. 
While the invention has been described through specific embodiments, routine 
modifications will be apparent to those skilled in the art and such modifications 
are intended to be within the scope of the present invention.   
 
What is claimed is: 
1. A method for inducing expression of human beta-globin in erythrocytes for 
use in prophylaxis and/or therapy of a hemoglobinopathy in an individual 
comprising introducing into erythrocyte progenitor cells a polynucleotide 
encoding: 
 i) a 5’ long terminal repeat (LTR) and a self-inactivating 3’ LTR; 
 ii) at least one polyadenylation signal; 
 iii) at least one promoter; 
 iv) a globin gene locus control region (LCR); 
 v) an ankyrin insulator element (Ank); 
 vi)  a Woodchuck Post-Regulatory Element (WPRE) configured such that 
the WPRE   does not integrate into a target genome; and 
 vii) a sequence that is a reverse complement of a sequence encoding 
modified human beta-globin comprising a βT87Q mutation (B-globinM), wherein 
the sequence encoding the B-globinM comprises a first intron (intron 1) between 
exon 1 and exon 2, and a second intron (intron 2) between exon 2 and exon 3 of 
said B-globinM sequence, wherein intron 2 comprises more than 476 nucleotides 
of human B-globinM intron 2 sequence; 
 wherein, subsequent to the introducing, the erythrocyte progenitor cells 
differentiate into erythrocytes, wherein the erythrocytes are present in the 
individual and the erythrocytes produce more human beta-globin than a control. 
 
2. The method of claim 1, wherein the control comprises a human beta-
globin value obtained from control cells, wherein the control cells comprise 
erythrocytes from an individual who has the hemoglobinopathy, wherein the 
erythrocytes are progeny of cells into which a control viral vector is introduced, 
the control viral vector comprising the 5’ LTR, the 3’ LTR, the at least one 
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polyadenylation signal, the at least one promoter, the LCR, the Ank, a WPRE, 
and the sequence encoding the B-globinM, but wherein the sequence encoding 
the B-globinM in the control viral vector comprises 476 or fewer nucleotides of 
the human B-globinM intron 2 sequence. 
 
3. The method of claim 1, wherein the lentiviral vector further comprise a 
sequence encoding a fusion of an Ldb1 transcription factor and a zinc finger (ZF) 
domain. 
 
4. The method of claim 1, wherein the lentiviral vector further comprises a 
sequence encoding an RNA polynucleotide that is a reverse complement of 
mRNA encoding transferrin receptor 1, and wherein the RNA polynucleotide 
comprises a microRNA or an shRNA sequence and is capable of decreasing 
transferrin receptor 1 mRNA in an RNAi-mediated process. 
 
5. The method of claim 1, wherein the erythrocyte progenitor cells comprise 
CD34+ cells, wherein the CD34+ cells are separated from the individual before 
the introducing the lentiviral vector to the cells, and wherein the CD34+ cells are 
introduced into the individual subsequent to the introducing of the lentiviral 
vector. 
 
6. The method of claim 1, wherein the intron 2 comprises 851 nucleotides of 
the adult human B-globinM intron 2 sequence. 
 
7. The method of any of claims 1, 2, 3, 4, 5 or 6, wherein the increased 
human beta-globin comprises adult hemoglobin, fetal hemoglobin, B-globinM, or 
a combination thereof. 
 
8. The method of claim 7, wherein the hemoglobinopathy comprises sickle-
cell anemia (SCA) or beta-thalassemia. 
 
9. A lentiviral vector for inducing expression of human beta-globin in 
erythrocytes and/or erythrocyte progenitor cells for use in prophylaxis and/or 
therapy of a hemoglobinopathy in an individual, the lentiviral vector comprising: 
 i) a 5’ long terminal repeat (LTR) and a self-inactivating 3’ LTR; 
 ii) at least one polyadenylation signal; 
 iii) at least one promoter; 
 iv) a globin gene locus control region (LCR); 
 v) an ankyrin insulator element (Ank); 
 vi)  a Woodchuck Post-Regulatory Element (WPRE) configured such that 
the WPRE  does not integrate into a target genome; 
 vii) a sequence that is a reverse complement of a sequence encoding 
modified adult human beta-globin comprising a βT87Q mutation (B-globinM), 
wherein the sequence encoding the B-globinM comprises a first intron (intron 1) 
between exon 1 and exon 2, and a second intron (intron 2) between exon 2 and 
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exon 3 of said B-globinM sequence, wherein intron 2 comprises more than 476 
nucleotides of adult human B-globinM intron 2 sequence. 
 
10. The lentiviral vector of claim 9, wherein the lentiviral vector further 
comprise a sequence encoding a fusion of an Ldb1 transcription factor and a zinc 
finger (ZF) domain. 
 
11. The lentiviral vector of claim 9, wherein the lentiviral vector further 
comprises a sequence encoding a RNA polynucleotide that a reverse 
complement of mRNA encoding transferrin receptor 1, and wherein the RNA 
polynucleotide comprises a microRNA or a shRNA sequence and is capable of 
decreasing transferrin receptor 1 mRNA in a RNAi-mediated process. 
 
12. The lentiviral vector claim 9, wherein the lentiviral vector is present in 
CD34+ cells, wherein the CD34+ cells have been separated from an individual 
who has a hemoglobinopathy. 
 
13. The lentiviral vector of claim 12, wherein the lentiviral vector is present in a 
virion. 
 
14. A pharmaceutical composition comprising viral particles, wherein the viral 
particles each comprise a RNA strand which comprises a lentiviral vector of any 
one of claims 9, 10, 11. 
 
15. A method of making a viral particle preparation for use in prophylaxis 
and/or therapy for one or more hemoglobinopathies comprising introducing a 
plasmid encoding a lentiviral vector of claim 1 into packaging cells which 
comprise a DNA packaging plasmid which encodes at least one virion protein, 
and a DNA envelope plasmid which encodes an envelope protein, and allowing 
expression of the virion protein and the envelope protein such that viral particles 
form, and separating the viral particles from the packaging cells. 
 
